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DELINEATING THE ROLE OF FATTY ACID METABOLISM TO IMPROVE 




 Colorectal cancer (CRC) remains a leading cause of cancer-related deaths 
in the world, comprising over 1 million new cases each year and over 500,000 
deaths. CRC, when detected at an early stage of disease development, can be 
effectively treated, with a 5-year survival rate of over 90%. Such standard 
treatments include surgical resection of the primary tumor in combination with 
adjuvant chemotherapy. However, even with advancements in surgical procedures 
and chemotherapeutic targets, when CRC progresses to a more advance stage, 
the 5-year survival rate decreases significantly to just under 14%. This stark 
decrease in patient survival rate can be directly contributed to the lack of effective 
chemotherapeutics as well as relapse, which occurs in 30-50% of patients treated 
for CRC and results in a far more aggressive disease. With such a large rate of 
CRC relapse and drastically low survival rates, the need for new therapeutic 
targets for the disease are particularly needed.  
 
Dysregulation of fatty acid (FA) metabolism has been identified as a 
hallmark of cancer and a key proponent to CRC development and progression. 
FAs are used for a multitude of purposes within the cell, such as signaling 
molecules, components of membrane synthesis, and most importantly, as a direct 
energy source. Two different pathways contribute to FA utilization in cancer cells. 
First, FAs can be synthesized de novo. FA Synthase (FASN), a key enzyme of de 
novo FA synthesis, catalyzes the synthesis of palmitate from acetyl-CoA and 
malonyl-CoA. Another prominent pathway utilized by cells to obtain FAs is 
exogenous FA uptake via transmembrane FA transporters including FA 
Translocase (CD36). CD36 is a multifunctional glycoprotein, is primarily involved 
in the binding and transportation of low-density lipoproteins and long-chain/ultra-
long-chain FAs. My research assessed the role of CD36 in CRC growth and 
metastasis as well as the relationship between CD36 and FASN, particularly, the 
aspect of this relationship when de novo lipid synthesis is inhibited using novel 
FASN inhibitors. 
 
 FASN upregulation has been previously shown to contribute to primary 
CRC growth and progression to metastasis. Chemical inhibition of FASN via a 
novel FASN inhibitor TVB-3664, has shown significant promise in the treatment of 
CRC in vitro by reducing CRC proliferation via a decrease is cellular respiration. 
Interestingly, pre-clinical evaluation of this inhibitor in patient derived xenografts 
(PDXs) in vivo suggests that high expression of FASN does not determine a 
positive response to FASN-targeted therapy and only approximately 30% of PDXs 
exhibit significant tumor reduction. These results suggest that there may be 
alternative pathways which may contribute to FASN inhibition resistance.  
 
CD36 has been studied in various diseases, including glioblastoma, breast, 
ovarian, and oral carcinomas, where it has been found to significantly contribute 
to disease progression and metastasis. However, CD36 has not yet been 
thoroughly investigated in CRC, and has not been studied in relation to de novo 
lipid synthesis. My studies show that CD36 is upregulated in CRC primary and 
metastatic tumors and an increased expression level of CD36 is associated with 
an increase in FA uptake. Furthermore, CD36 inhibition significantly decreases 
proliferation of CRC established and primary cell lines in vitro, and knockdown of 
CD36 reduces subcutaneous xenograft tumor growth in vivo. Most excitingly, 
inhibition of FASN significantly and specifically upregulates CD36 expression, but 
not other FA transporters, in human tissues, established and primary cell lines, and 
genetically modified mice with heterozygous and homozygous deletion of FASN. 
This upregulation of CD36 in the presence of FASN inhibition resulted in a CD36 
specific increase in the uptake of exogenous FA analogues, further supporting the 
role of CD36 as a potential compensatory mechanism to FASN-targeting therapy. 
Additionally, inhibition of FASN and CD36 in combination resulted in an additive 
effect on the reduction of CRC cell proliferation.  
 
Late-stage metastatic CRC has a substantially lower rate of 5-year survival 
compared to earlier stage disease. As aforementioned, in addition to primary CRC 
cell survival and proliferation, CD36 was shown to be further upregulated in CRC 
metastatic tissues. My studies demonstrate that CD36 promotes CRC cell invasion 
and colony formation in vitro. Additionally, an increase in CD36 is associated with 
more metastatic CRC cell lines and promotes metastasis of CRC cells in vivo. 
Interestingly, CD36 expression is associated with matrix-metallopeptidase-28 
(MMP28), the newest member of the matrix-metallopeptidase family of proteins. 
MMP28 is involved in the degradation of the extracellular matrix (ECM), particularly 
the disassembly of collagen fibers within cell-cell adhesions. MMP28 has been 
suggested in the metastasis of various diseases including lung and gastric cancer. 
MMP28 had not yet been investigated in CRC. Knockdown of CD36 decreases 
MMP28 expression and increases the expression of e-cadherin, a critical protein 
involved in cell-cell adherent junctions and whose loss is a well-known marker for 
epithelial to mesenchymal transition (EMT) in various cancers. Furthermore, 
knockdown of MMP28 is sufficient to significantly upregulate e-cadherin 
expression suggesting that CD36 potentially regulates metastasis through early 
EMT via the upregulation of MMP28 and loss of e-cadherin. 
 
New therapeutic strategies in the treatment of CRC are urgently needed to 
improve the survival rates of those patients with late-stage disease. Altered FA 
metabolism is a common characteristic of many cancers including CRC. The 
studies described here investigate the role of CD36 in CRC and upregulation of 
CD36 as a potential compensation mechanism to FASN-targeted therapy which is 
currently being tested in several clinical trials. The results of my studies 
demonstrate that CD36 may present a viable target for treatment of both primary 
and metastatic CRC. Furthermore, this study provides the rationale for targeting 
CD36 in combination with FASN inhibitors and demonstrates that inhibition of 
CD36 increases efficacy of FASN-targeted therapy via a reduction of the free-FA 
pools available to CRC tumor cells. Further investigation into the mechanistic 
functions of both CD36 and FASN in CRC as well as the contribution of CD36 to 
CRC metastasis is needed to provide more efficacious treatment strategies of 
CRC.         
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CHAPTER 1. INTRODUCTION TO COLORECTAL CANCER, FATTY ACID 
METABOLISM, FATTY ACID SYNTHASE, AND FATTY ACID TRANSLOCASE 
 
1.1 Colorectal Cancer  
 
Colorectal cancer (CRC) is the leading cause of non-smoking related 
cancer deaths in the world, and the second leading cause of cancer related deaths, 
with estimates of more than 145,000 new cases in the United States, including 
more than 50,000 new deaths in 2020 [1, 2]. In 2018, diagnosed cases of CRC 
were over 1.8 million worldwide, with over 800,000 deaths, a number which 
accounted for almost 10% of all cancer related deaths in the world [3]. Current 
models predict that CRC diagnoses will increase to over 2.5 million annually by 
2035 [4]. As with many cancers, CRC has historically been viewed from the 
perspective of a disease directly related to age. However, when looking at 
epidemiological studies over the past 40 years, incidence rates for CRC in younger 
age groups, those 20-49 years, has increased by over 47 % [5]. Patients within 
high-risk demographics are encouraged to receive asymptomatic screening for 
CRC as this has been shown to reduce mortality rates of the disease significantly 
through both the removal of lesions prior to disease development as well as earlier 
stage CRC diagnosis [6-9]. 
 
CRC, as with many of the oncogenic diseases, is heterogenous and can be 
classified into several molecular sub-types [10-12]. The CRC Subtyping 
Consortium, using six independent molecular classification systems, have 
recognized four unique molecular subtypes of CRC which are: Microsatellite 
Instability Immune (MII), Canonical, Metabolic, and Mesenchymal [10, 11, 13]. Of 
these subtypes, the most prevalent at 37% is the Canonical, which is characterized 
with marked wingless-related integration site (WNT) and MYC signaling activation. 
CRCs typical of the Canonical subtype exhibit an initial loss of the adenomatous 
polyposis coli (APC) gene followed by an activating mutation of the KRAS signaling 
pathway in combination with the loss of tumor protein-53 (TP53) [13, 14]. Clinically, 
nearly 40% of Canonical subtype CRC tumors are diagnosed at Stage III, however 
this subtype represents the highest overall 5-year survival rate at nearly 80% [10]. 
This is followed by the Mesenchymal subtype at 23% of all CRCs, exhibiting 
significant transforming growth factor beta (TGFβ) activation with stromal invasion, 
angiogenesis, and can be both with and without prominent Wnt signaling. Tumors 
of this subtype display pathologically serrated legions, with cells representing a 
mesenchymal phenotype [15]. Cancer associated fibroblast (CAFs) with increased 
TGF-β signaling profiles, as well as a prominent inflammatory microenvironment, 
are also common of this sub-type [10, 13]. These are followed up by the MII 
subtype at 14% and consisting of significant microsatellite instability and a 
pertinent immune system activation. The MII subtype is specifically represented 
pathologically by the presence of serrated polyp precursor legions, consisting of 
high BRAF mutation rates, loss of tumor suppressor function and missed-match 




MMR deficiency results in a hyper mutated genetic profile, with nearly a 20-fold 
increase in mutation rate per 10^6 base pairs compared to microsatellite stable 
tumors [10, 13, 16].  Lastly, the Metabolic subtype comprises 13% of all CRCs and 
possesses increased metabolic dysregulation, particularly in the DNA repair, 
glutaminolysis, lipogenesis and cell cycle pathways [10, 11, 13, 14]. More in-depth 
investigation into the various subtypes of CRC and their unique molecular profiles 
may increase treatment efficacy for CRC. 
 
1.2 Treatment Strategies for CRC 
 
 As previously mentioned, CRC rates, although declining in those ages over 
50, are increasing significantly in younger populations and CRC remains the 
second most common cause of cancer related deaths in the world [5, 17]. Those 
patients diagnosed with early stage CRC have nearly a 10 fold increase in 5 year 
survival rate when compared to later stage disease with more distant metastases 
[18, 19]. For those with earlier stage disease, the therapeutic approach is much 
simpler, relatively speaking, than those with later, more advanced CRC. 
 
 A typical treatment strategy for those with stage 0-I CRC is surgical 
excision of the cancerous lesion, typically contained within a polyp. In lesions not 
contained within a polyp, or if the edge of the polyp still contains cancerous cells, 
a partial colectomy may be recommended to remove the section of the colon with 
disease [20, 21]. Those patients with more progressed disease, including some 
stage II and stage III-IV CRC, surgical excision of the primary tumor and/or partial 
colectomy is recommended in combination with adjuvant chemotherapy. Such 
chemotherapeutic agents used in combination with surgical resection are non-
targeted drugs and include 5-fluorouracil, leucovorin, oxaliplatin and capecitabine 
[20, 22]. 5-fluorouracil (5FU) was one of the earliest chemotherapeutic anticancer 
agents identified and is an antimetabolite, inhibiting the enzyme thymidylate 
synthase, thus preventing the production of thymidine and consequently impeding 
DNA synthesis and cell proliferation [23, 24]. 5FU is used across a wide range of 
diseases including breast, skin, and head and neck cancers [25]. Although it has 
seen some success in treating CRC, 5FU only produces significant response in 
<20% of patients when used alone, and for that reason it is typically used in 
combination with other therapeutics. [26, 27]. Combination of 5FU with leucovorin 
as well as oxaliplatin have seen increases in treatment efficacy [28]. Leucovorin, 
also known as folinic acid, significantly enhances the binding potential of 5FU with 
thymidylate synthase, increasing patient response to 26-43%, depending on 
treatment course [29]. Oxaliplatin is a third-generation platinum compound, with a 
unique 1,2-diaminocyclohexane moiety [30]. Analogous with other platinum-based 
therapeutics, oxaliplatin derived cytotoxicity is due to platinum induced DNA 
crosslinks, typically between two guanines, or a guanine and adenine base pair, 
resulting in inter- and intra-strand platinum-DNA adducts. Due to the 1,2-
diaminocyclohexane moiety however, these adducts are significantly bulky, 
resulting in a more effective blocking of DNA-mismatch repair enzymes, and 




platinum-based therapies [30, 31]. Oxaliplatin alone produces relatively low 
response rates in patients, approximately 20%, however, used in combination with 
the 5FU and leucovorin, patient response rates significantly increase, to nearly 
50%, accompanied by an increase in progression free survival [32-34]. Together, 
this combined treatment regimen of oxaliplatin, 5FU and leucovorin is known as 
the FOLFOX regimen. Other regimens consisting of multiple chemotherapeutics 
agents in combination include FOXFIR, a mixture of 5FU and irinotecan, as well 
as XELOX, an oxaliplatin and capecitabine mixture. The efficacy of these varying 
regimens is comparable to each other [35]. Together these regimens remain the 
standard approach for first-line treatment of CRC.  
 
Due to the high mortality of advanced stage disease, there are several 
ongoing efforts to establish effective targeted therapies for the treatment of CRC. 
There has been emphasis on targeting the epithelial growth factor receptor (EGFR) 
pathway including the protein EGFR, human epidermal growth factor receptors 
(HERs), v-raf murine sarcoma viral oncogene homolog B1 (BRAF), and encoding 
phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K). Within CRC patient 
populations, those patients with aberrant EGFR upregulation comprise up to 77% 
of the total CRC patients [36]. Furthermore, nearly 5% of CRC patients also exhibit 
HER2 overexpression [37, 38]. Of the targeted therapies for EGFR, those most 
prominent include the monoclonal antibody cetuximab and its fully humanized 
derivative panitumumab [39, 40]. These therapeutics work to induce EGFR 
degradation after biding to the receptor in its extracellular domain and have shown 
great promise as first-line treatment for CRC [35, 39]. However, 10% of CRC 
patients also exhibit oncogenic mutations in BRAF, which has been hypothesized 
to contribute to anti-EGFR therapeutic resistance [41]. Current treatment of CRC 
with mutant BRAF consists of using BRAF inhibitors, such as vemurafenib, in 
combination with upstream, EGFR inhibitors such as cetuximab [42]. This 
combination is necessary, as patients treated with BRAF inhibitors alone often see 
no significant change in progression-free survival [35, 43, 44]. Additionally, it is 
suggested that inhibition of EGFR can also upregulate the expression of HER2, 
which, due do similar downstream RAS and PI3K signaling, can compensate for 
EGFR inhibition [45]. To target HER2, a combinational treatment of trastuzumab 
and pertuzumab, or trastuzumab and lapatinib are utilized [46, 47]. PI3K mutations 
coincidentally can lead to downstream activation of AKT and resistance to EGFR 
inhibition. Currently, several studies are investigating potential inhibitors to PI3K to 
use in combination with EGFR targeted therapy, however much more 
understanding is needed for effective inhibition of PI3K within the clinical setting 
[35].  
 
Another prominent pathway which has become the focus of targeted 
intervention with metastatic CRC is the vascular endothelial growth factor (VEGF) 
pathway, which is responsible for the regulation of angiogenesis [48]. Interactions 
between VEGF-A and vascular endothelial growth fact receptor 2 (VEGFR-2) 
result in the activation of downstream pathways including the previously mentioned 




gene amplification, while composing a relatively small number of total CRC 
patients, have disease that is typically more aggressive and results in significantly 
lower 5-year survival rates [49]. The monoclonal antibody bevacizumab is currently 
the prominent antiangiogenic therapy targeting VEGF and still the only Food and 
Drug Administration (FDA) approved first-line therapy which targets VEGF. 
However, various new therapeutic agents are being developed and tested in phase 
II and III clinical trials with some being approved for second-line treatment of CRC 
[35, 50]. Due to the high complexity and varying pathway intersections involved in 
the VEGF pathway, resistance to VEGF targeted therapy can frequently be 
observed [35]. Strategies targeting VEGF in combination with other potential 
pathways of compensation, such as the fibroblast growth factor (FGF) and c-Met 
pathways as well as angiopoietin-2 signaling, have shown promise in pre-clinical 
studies [51, 52]. However, in some early clinical trials, several strategies have 
failed to yield significant results and more investigation is needed to improve 
treatment modalities involving the targeting of VEGF [53].  
 
More recently, advances in understanding of the immune checkpoint 
pathway has led to development of multiple therapeutics which aim to enhance the 
recognition and clearance of cancer cells by the immune system [54]. Two 
prominent agents used to target the immune-checkpoint pathway in metastatic 
CRC were pembrolizumab and nivolumab [35]. These treatments are both 
monoclonal antibodies which target programmed cell-death protein 1 (PD-1) on 
the tumor cell surface and which, through binding to programmed cell-death 
protein 1-ligand (PDL-1), activates T-cell dysfunction and tolerance, resulting in an 
escape by the tumor cell from the surveillance of the immune system [55-57]. Both 
therapeutics earned FDA-approval after they displayed significant patient 
response in those patients whose tumors exhibit high microsatellite stability (MSI-
H) [58, 59]. However, those patients with intact mismatch repair (MMR) showed 
little to no response to these immune-checkpoint targeted therapies. Several other 
potential treatments are currently under investigation and other therapeutic targets 
within the immune-checkpoint pathway are also being explored with the hopes of 
broadening the range of patients who respond well to this type of therapeutic 
strategy. 
     
1.3 CRC Treatment Efficacy 
 
 Screening for CRC, which typically consists of a colonoscopy and is the first 
line of defense in the prevention of CRC, has drastically increased within the 
United States in recent years [60]. Those patients between the ages of 50-75 years 
have significantly increased their up-to-date screening rates since 2005, going 
from 46.8% to 68.8% in 2018 [61, 62]. Consequently, the incidence and mortality 
rates for CRC in these older populations have seen some decline since the 
implementation and higher participation in early CRC screening [63]. Despite this 
increase in screening and early CRC detection, late-stage CRC remains to be ever 
problematic and with this, disease relapse and mortality rates continue to remain 




not yet spread to distant tissues while 20-25% percentage of patients are 
diagnosed with late-stage metastatic CRC. [2, 64]. Those whose CRCs are 
diagnosed at an early stage (Stage I-III) have a significantly higher 5-year survival 
rate when compared to those diagnosed with much more progressed disease 
(Stage IV), which has a 5-year survival rate of less than 14% [5, 8, 65] (Table 1.1).  
Due to this significant reduction in survival of late-stage CRC, emphasis on 
discovering new therapeutic strategies for late-stage CRC is necessary. 
 
 Achieving complete remission, or more specifically pathological complete 
response (pCR), which is the complete absence of cancerous tissues via biopsy 
or surgical resection, has been shown to significantly improve patient 5-year 
survival. Those who do achieve pCR have an average 5-year survival rate of 83% 
compared to those patients who do not, which have an average 5-year survival 
rate of only 66% [66]. Those who are diagnosed with early stage, localized CRC 
see almost 100% pCR after surgical resection [67]. Historically, those diagnosed 
with later stage, invasive and/or metastasized CRC would likely only receive minor, 
palliative primary surgical resection due to their increased tumor burden, which is 
typically present with significant liver metastasis [67]. Due to advances in new 
therapeutic approaches, patients with Stage II and III CRC can receive 
neoadjuvant therapy; that is therapy which is administered pre-operatively to 
reduce tumor burden to an operational size and can exhibit almost a 25% pCR rate 
[68]. Those diagnosed with Stage IV disease, even if qualifying for curative 
surgery, still exhibit a poor response rate [68]. This discrepancy between patient 
groups can be contributed to the lack of pCR and the heterogeneity of metastatic 
burden observed between different late stage CRC patients, resulting in a 
significantly higher rate of disease recurrence [69]. 
 
 Although several strategies have been employed to detect CRC recurrence 
early, where it can be more effectively treated, disease recurrence remains high 
[70]. Of all CRC patients treated, approximately 40% experience some sort of 
recurrent disease [71]. More specifically, of all patients diagnosed with at least 
potentially curable disease, up to 60% will relapse, often with more difficult-to-treat 
metastatic disease [70]. The most critical period in which recurrence can occur is 
3 years following completion of definitive care [72]. Strategies currently used to aid 
in the early detection of recurrent CRC which have important clinical significance 
include blood tests to monitor liver enzyme levels and regular imaging of both the 
liver, the most common site of metastasis in CRC, and the lungs [70, 73, 74]. For 
example, if monitored closely, up to 20% of recurrent liver metastasis can be 
successfully surgically removed, with significant increases in patient survival [75-
77]. However, a large proportion of patients diagnosed with CRC could greatly 
benefit in better preventative and detection strategies against recurrent CRC. 
 
 CRC patients diagnosed with local advanced, or late-stage disease are still 
in need of more effective therapeutic strategies. More effective therapeutic targets 
could improve definitive treatment of both primary and metastatic CRC as well as 




including that of cellar metabolism, specifically altered fatty-acid metabolism, have 
been implicated in CRC progression and metastasis [78]. Dysregulation of lipid 
metabolism is a hallmark of cancer; however further understanding of the 
intricacies in this complex metabolic pathway is required to identify appropriate 
therapeutic targets for CRC.  
 
1.4 Fatty Acids and Fatty Acid Metabolism 
 
1.4.1 Fatty Acid Structure and Distribution 
 
 Fatty acids (FAs) consist of a carboxylic acid which contain a long, aliphatic 
side chain. This side chain of carbons can vary in number typically from 2-26 [79]. 
Categorically, FAs can be grouped in four groups based on the length of their 
aliphatic side chain: short chain (2-6 carbon atoms), medium chain (8-12 carbon 
atoms), long chain (14-18 carbon atoms), and very long chain (20-26 carbon 
atoms) [79, 80]. FAs can be defined as saturated (SFA) or unsaturated (UFA) 
where SFAs consist of molecules with no carbon-carbon double bonds, meaning 
the entire molecule is completely saturated with hydrogen atoms aside from the 
carboxyl group. UFAs contain at least one carbon-carbon double bond [81]. The 
most common types of FAs found within mammals are the long-chain and very-
long-chain FAs, which include palmitic and oleic acid [80].  
 
Typically, FAs are not found in most organisms as stand-alone molecules, 
but instead, they are most often in the forms of either cholesteryl esters, 
phospholipids, or triglycerides. Cholesteryl esters are a FA bound to a cholesterol 
molecule via an ester bond between the carboxyl group of the FA and the hydroxyl 
group of the cholesterol. These molecules, when hydrolyzed at the ester bond, 
release a free FA (FFA) and the cholesterol molecule for an energy source or 
membrane and lipoprotein formation [82]. Phospholipids contain a hydrophilic 
phosphate group bound to a hydrophobic region consisting of one or two FAs, 
which are all bound to each other via a glycerol molecule [83]. These molecules 
are then used for structural purposes, specifically membrane synthesis throughout 
the cell. Triglycerides (TGs) are esters formed by a glycerol molecule and three 
FAs. TGs are the primary component of fat within the body [81]. As with FAs alone, 
TGs can be considered saturated or unsaturated. The FA chains contained within 
the TG can all vary in length, but typically consist of either 16, 18, or 20 carbon 
atoms. Primarily, TGs are metabolized by a member of the pancreatic lipase family 
of enzymes, which hydrolyzes the ester bond within the TG, releasing the three 
FFAs and the glycerol molecule in a process known as lipolysis [81]. These FAs 
can then be readily absorbed in the intestine and utilized by the cells [84].  
  
1.4.2 Fatty Acids as Building Blocks of Cellular Membranes 
 
 The most abundant and fundamental building block of all cellular 
membranes are phospholipids [85]. These critical components account for 50-60% 




both hydrophilic and hydrophobic properties (also known as amphiphilic), can form 
lipid bilayers [86]. The FA component of these phospholipids form the hydrophobic 
tails, which due to entropy, cause the spontaneous formation of the bi-lipid layer in 
aqueous solutions [85]. Typically, the phospholipid consists of two FA tails, one of 
which is unsaturated with one or more double bonds, and the other is saturated, 
with no double bonds present [83, 87]. This heterogeneity allows the numerous FA 
tails of the phospholipids to arrange in such a way spatially that they are tightly 
packed yet still fluid relative to each other [87]. The fluidity of the bi-lipid layers is 
critical to the normal function of various proteins which are embedded within the 
membrane as well as the diffusion of other biomolecules [88]. Phospholipid 
molecules can diffuse laterally within the same monolayer, as well as flip-flop 
across monolayers, although the flip-flop is much less common [87]. To facilitate 
the movement of new phospholipid molecules across the two monolayers for the 
purpose of new membrane synthesis and membrane repair, the cell utilizes 
phospholipid translocator enzymes to catalyze the process [87]. The degree of 
fluidity of the membrane can also vary based on the variations in unsaturation of 
the FA tails. More unsaturated tails, containing more double bonds, allow for a 
more fluid membrane due to the spatial requirement of the double bonds and thus 
the less densely packed lipid molecules [87]. The unique dynamics of the 
phospholipid bilayer allow the cellular membranes to be incredibly diverse while 
serving as a strong barrier for the entire cell from its external environment, as well 
as separating the various compartmental organelles and the nucleus within the cell 
[85, 86]. 
 
Alongside phospholipids, FAs also contribute to the formation of numerous 
other types of lipids found within cellular membranes including sterols (primarily 
cholesterol), and sphingolipids [89]. Sterols, with cholesterol being the most 
prominent type in mammalian cells, comprise nearly 30% of the cellular membrane 
[90]. Cholesterol can be synthesized de novo or transported and internalized in the 
form of low-density lipoproteins (LDLs) [91].Cholesterol contributes significantly to 
the structural integrity of cell membranes as well as helps mediate membrane 
fluidity [92, 93]. Sphingolipids are lipids which are composed of a spingoid base 
backbone, a backbone comprised of aliphatic amino alcohols, the most common 
being sphingosine, attached to a FA via an amide bond [94]. Sphingolipids 
contribute structurally to cell membranes as well as serve as cell signaling 
molecules [95]. Sphingolipids can frequently associate with cholesterol within the 
cell membrane to form lipid rafts [96]. These relatively more-dense areas of the 
cell membrane can contain various signaling proteins and contribute to overall 
membrane fluidity [97, 98]. It is proposed that lipid rafts facilitate cell signaling by 
providing spatial arrangements of various proteins, allowing for more precise 
protein-protein interactions and thus contributing to numerous signaling cascades 
[99]. 
 





Furthermore, aside from membrane formation, FAs can be utilized as lipid 
signaling molecules. Such molecules include prostaglandins, which are 
synthesized using arachidonic acid (AA), the 20-carbon unsaturated fatty-acid, and 
are key mediators of inflammatory responses to infection or injury [100, 101]. Other 
signaling molecules synthesized from AA, also known as eicosanoids, include 
thromboxane’s and leukotrienes, which are responsible for blood clotting and 
immune function regulation, respectively [102]. 
 
As previously mentioned, sphingolipids, aside from facilitating cell signaling 
through lipid rafts, can themselves also serve as signaling molecules within the 
cell [95, 99]. Sphingolipids, particularly their metabolites ceramide, sphingosine, 
and sphingosine-1-phosphate, contribute to the signaling of cellular differentiation, 
cellular apoptosis and proliferation [95]. Ceramide, produced by the hydrolysis of 
sphingomyelin by sphingomyelinase, is typically the primary secondary messenger 
in sphingolipid dependent cell signaling [103]. Ceramide has been shown to be 
directly related to cellular apoptosis [104]. Conversely, sphingomyelin synthase 
facilitates the synthesis of sphingomyelin from ceramide, together forming the 
sphingomyelin cycle [105]. The phosphorylation of sphingosine by the two kinases 
sphingosine kinase 1 and 2 (SPHK1 and SPHK2) yields sphingosine-1-phosphate 
(S1P) [106]. S1P is involved in various cell signaling pathways including cell growth 
and suppression of apoptosis [107, 108]. Interestingly, S1P directly mediates 
apoptosis suppression through the inhibition of ceramide signaling, thus creating 
a well-regulated balance in which intracellular levels of ceramide and S1P 
contribute to overall cell fate [108]. 
 
In addition to the aforementioned FA derivatives involved in cell signaling, 
FFAs themselves can be utilized as cell signaling molecules [109]. FFAs can 
stimulate the transcription of numerous genes involved in various metabolic 
pathways. SFAs can stimulate genes within the sterol-regulatory element binding 
protein 1 (SREBP1) pathway, which in turn is responsible for the synthesis of other 
FAs and cholesterol [110, 111].  UFAs can however stimulate fatty-acid oxidation 
and in turn prevent further production of new UFAs [112].     
   
1.4.4 Fatty Acids as An Energy Source 
 
 As previously mentioned, FAs are an important source of energy regarding 
cellular metabolism [79, 80, 102]. FAs have nearly twice the yield of energy 
compared to carbohydrates [113]. The key element of FAs which make them a 
prospective energy source for cells is their long aliphatic side chain. When a FFA 
is present within the cell, the primary method in which they are utilized for energy 
is FA beta-oxidation (FA β-oxidation), which describes the formation of acetyl-
coenzyme-A (acetyl-CoA) molecules via the breakdown of long chain FAs [79, 
114-116].  
 
For a FA to first enter the FA β-oxidation pathway, a coenzyme-A (CoA) 




This reaction is also known as FA activation, and is catalyzed by a cytosolic acyl-
CoA synthase(ACS) enzyme [117]. The specific acyl-CoA synthase used is 
dependent on the length of the FA. FA β-oxidation occurs within the mitochondria, 
however long chain FAs and fatty acyl-CoA molecules cannot freely translocate 
across the mitochondrial inner and outer membranes [79, 114, 116]. To overcome 
this limitation, a specific transport mechanism, the carnitine shuttle system, is 
utilized. A carnitine molecule is added to the newly formed fatty acyl-CoA molecule 
by carnitine palmitoyl transferase 1 (CPT1) on the surface of the outer 
mitochondrial membrane. The resulting fatty acylcarnitine can then be transported 
across the outer mitochondrial membrane and into the intramembranous space 
between the inner and out membranes [114, 116]. To then cross the inner 
mitochondrial membrane, the fatty acylcarnitine is transported via acylcarnitine 
translocases. Once across the inner mitochondrial membrane, carnitine palmitoyl 
transferase 1 (CPT2) removes the carnitine molecule from the fatty-acyl-CoA, and 
the carnitine is shuttled back across the inner and outer membranes to be recycled 
for further FA transport [114, 116]. Of these phases, the transfer of carnitine to the 
fatty-acyl-CoA by CPT1 is the rate limiting step, with malonyl-CoA acting as an 
inhibitor of CPT1, reducing FA β-oxidation [114]. In periods of fasting, malonyl-
CoA levels fall, favoring FA transport across the mitochondrial membrane and 
increased beta oxidation [80, 114]. 
 
Once the fatty acyl CoA is completely inside the mitochondria, FA β-
oxidation can occur. The first step in FA β-oxidation is the removal of two hydrogen 
molecules from the beta and gamma carbons of the acyl-CoA by acyl CoA 
dehydrogenase and an flavin adenine dinucleotide (FAD) molecule [114-117]. This 
results in the production of one FADH2 molecule and a 2-trans-enoyl CoA. The 2-
trans-enoyl CoA is then hydrated across the same two carbons by enoyl-CoA 
hydratase, resulting in an L-β-hydroxyacyl CoA. The resulting hydroxyl group 
within the L-β-hydroxyacyl CoA is oxidized by 3-hydroxyacyl-CoA dehydrogenase 
and a nicotinamide adenine dinucleotide (NAD+) molecule resulting in β-ketoacyl 
CoA and an NADH [114-117]. Lastly, the β-ketoacyl CoA is cleaved by a thiol group 
of another, independent CoA molecule, by β-ketothiolase between the beta and 
gamma carbons. This results in a single acetyl-CoA molecule consisting of the 
alpha and beta carbons of the original fatty acyl-CoA, and a new fatty acyl-CoA 
molecule that is two carbons shorter [114-117]. This process then repeats itself 
until the final four carbons from the original acyl-CoA chain are cleaved into two 
acetyl-CoA molecules [114-117]. Therefore, for each cycle of FA β-oxidation, one 
acetyl-CoA molecule is produced along with one FADH2 and one NADH. The 
acetyl-CoA can then enter the tricarboxylic acid cycle (TCA) where it is oxidized to 
form three more NADH molecules as well as one more FADH2 and a single 
adenosine triphosphate (ATP), which is the primary molecule used for energy 
within the cell. The NADH and FADH2 molecules are then further utilized within the 
electron transport chain, where each NADH molecule can generate 3 ATP and 







1.5 Fatty Acids Acquisition: Synthesis vs. Uptake of Dietary FAs 
 
There are multiple pathways in which cells can acquire FAs (Figure 1.1). 
When FAs are released from fat tissue, more specifically from triglycerides via 
lipolysis as described previously, the FFAs are then transported throughout the 
circulatory system, typically chaperoned by albumin [119]. In this form, FAs can 
then be incorporated into most cell types within the body via specific FA 
transporters. Such FA transport molecules include the FA transport family of 
proteins (FATPs), FA binding proteins (FABPs), and FA translocase (CD36) [120]. 
These FFAs are then typically utilized as an energy source via FA beta oxidation 
but can also be used for a variety of purposes as mentioned above.  
 
Alternatively, cells may synthesize FAs de novo through the de novo FA 
synthesis pathway. This pathway describes the method in which acetyl-CoA and  
malonyl-CoA, are converted into long-chain FAs [121]. This process involves the 
critical enzymes acetyl-CoA carboxylase (ACC) which carboxylates acetyl-CoA to 
form malonyl-CoA, and FA synthase (FASN), which synthesizes long chain FAs 
from malonyl-CoA [122]. FAs synthesized via de novo lipid synthesis are then 
utilized for both membrane construction and as an energy source. 
 
Both pathways in which FAs can be obtained or synthesized are the major 
contributors to FA metabolism and are well regulated. The sterol regulatory 
element-binding proteins (SREBPs) are important transcription factors in the 
regulation of genes involved in both de novo lipogenesis and the uptake of 
exogenous cholesterol [123, 124]. Such genes involved in the SREBP regulation 
of de novo lipid synthesis include citrate carrier protein solute carrier family 25 
member 1 (SLC25A1), which specifically contributes to glucose-mediated lipid 
synthesis by shuttling citrate from inside the mitochondria across the mitochondrial 
membrane and into the cytosol where it serves as a precursor to de novo FA and 
cholesterol synthesis [125, 126]. In relation to the regulation of exogenous FA 
uptake and utilization, the peroxisome proliferator-activated receptor (PPAR) 
family of proteins have been shown to be involved [127]. In liver and intestinal 
tissues, increased activation of PPARα increases transcription of FATPs and 
ACSs, which are mediators of FA transport and activation [127]. Additionally, 
PPARγ activates the transcription of FATPs and ACS in adipose tissues, 
suggesting that increases in exogenous FA uptake in dependent on tissues 
specific signaling cascades[127]. The regulation of other important proteins 
involved in de novo lipid synthesis and exogenous FA uptake, such as FASN and 
CD36, is still being investigated and much work is left to be done.   
 
1.6 Fatty Acid Metabolism Dysregulation and Cancer 
 
 Altered FA metabolism has long been established as a hallmark of cancer 
[128-130]. Cancer cells are typically rapidly dividing and require significantly larger 




primary component of lipid membranes, which are required for newly dividing cells, 
are a prime resource for cancer cells [123, 131]. Specifically, cancer cells have 
been shown to utilize FAs to sustain proliferation and meet their energy demands 
in times of high metabolic stress [122]. 
 
 Increased levels of FAs and FA metabolism have been shown to promote 
cell proliferation and disease progression in multiple cancers [78, 123, 132]. For 
example, ATP citrate lyase (ACLY) is an important enzyme linked to glucose 
metabolism and is involved in lipid synthesis through the conversion of citrate to 
oxaloacetic acid and acetyl-CoA [133]. ACLY promotes the growth of lung 
carcinoma cells in vitro and is a poor prognostic factor for patients with non-small 
cell lung cancer [134, 135]. Furthermore, ACLY has also been implicated in the 
tumor progression and as a poor prognostic factor in other cancers including 
prostate, breast, bladder, and hepatocellular carcinoma [136-139]. Conversely, 
proteins involved in the uptake of exogenous FAs have also been implicated in the 
promotion of cancer [123]. The low-density lipoprotein receptor (LDLR) family of 
proteins are responsible for the binding of exogenous LDLs and internalizing them 
[91]. These receptors have been shown to be upregulated and significantly 
contribute to tumor growth in glioblastoma [140]. Additionally, various members of 
the FATPs and FABPs have been implicated in cancer progression, including 
FABP4 in the promotion of breast cancer tumor proliferation and FATP4 in the 
tumorigenesis and tumor progression of renal cell carcinoma [141, 142]. 
 
Other proteins have been shown to be involved the dysregulation of FA 
metabolism in numerous diseases via the regulation of de novo lipid synthesis and 
exogenous FA transport [123, 124, 132]. The SREBP family of proteins have been 
shown to promote tumorigenesis, cell proliferation, and disease progression in 
numerous cancers including glioblastoma, renal cell carcinoma, hepatocellular 
carcinoma, hepatocellular carcinoma, prostate cancer, and CRC [143-146]. For 
example, SREBP1 and SREBP2 were found to contribute to CRC glycolysis, FA 
oxidation, and mitochondrial respiration and inhibiting both transcription factors 
lead to a reduction in CRC cell proliferation [143]. Additionally, SREBP-1 
upregulates LDLR signaling in glioblastoma [140]. However, there is some 
controversy over the regulation of some FA metabolism proteins and cancer 
progression, including that of PPAR regulation of FABPs. PPARα induced 
expression of FABPs has been shown to both correlate with hepatocellular 
carcinoma progression as well as have antitumorigenic effects [147, 148]. Further 
understanding of the intricacies of FA metabolism regulation is required if new 
therapeutic targets are to be properly identified.    
 
In CRC,  aberrant FA metabolism and increased levels of FAs have been 
shown to promote CRC cell proliferation and disease progression [78]. 
Understanding mechanisms of dysregulated lipid metabolism and identifying 
potential therapeutic targets within this pathway are potential strategies in 
developing new therapeutic approaches for CRC. Interestingly, no work has 




uptake in CRC. CD36 is suggested to be involved in the progression of 
glioblastoma, oral, ovarian, and prostate cancer while FASN has been implicated 
in the promotion of CRC progression and metastasis [149-154], but the crosstalk 
between these two proteins has not been described before. My work provides new 
insight on the interconnection of these proteins during CRC progression and 
metastasis and provides the rationale for developing new therapeutic strategies 
targeting lipid metabolism in CRC.  
 
1.7 FASN Structure and Regulation 
 
 FASN not a single enzyme, but in fact is a homodimer of two identical 
polypeptide subunits, with each subunit containing an entire system of seven 
enzymatic domains [155]. The enzyme contains three catalytic domains within the 
N-terminus which are the ketoacyl synthase (KS) domain, the 
malonyl/acetyltransferase (MAT) domain, and the dehydrase (DH) domain [155, 
156]. The enzyme also consists of four separate domains in the C-terminus: the 
enoyl reductase (ER), ketoacyl reductase (KR), acyl carrier protein (ACP) and the 
thioesterase (TE) domains [155, 156]. Those enzymes at the N-terminal domain 
are primarily responsible for the binding of substrates, which are acetyl-Coa and 
malonyl-CoA. Those enzymes contained within the C-terminal domain are 
responsible of reduction of the newly forming FA precursor, and ultimately release 
of palmitate by the TE domain [156]. The ACP domain, which contains a prosthetic 
4’-phosphopantetheine group, is responsible for the shuttling of all intermediates 
throughout the FA synthesis process [157, 158]. There are currently multiple 
models which predict the exact molecular structure of FASN. The current model of 
FASN arrangement suggests that the two identical subunits are arranged 
antiparallel, thus resulting in two active centers that are composed of the KS 
domain, responsible for chain elongation, and the ACP, KR, and ER domains, 
which are responsible for reduction. Therefore it is understood that FASN has two 
active centers that can act independently of each other and operate simultaneously 
[159]. 
 
 It has previously been shown that FASN is strictly regulated by nutritional 
and hormonal stimuli [160, 161]. It has been shown that high-carbohydrate diets 
and increased blood insulin levels significantly upregulate FASN expression [162]. 
Regulation of FASN is not known to be due to covalent modification or due to 
allosteric regulation. Instead, the regulation of FASN is primarily at the 
transcriptional level [163]. FASN contains a 147-base pair (bp) region within its 5’ 
promoter in which a sterol regulatory element (SRE), a specific sequence of 5′-
ATCACCCCAC-3′ in which SREBPs can bind, is present at the150bp [164-167]. 
Along with this SRE, there are two regions containing an enhancer-box (E-box), 
one at the 65bp and another more upstream at the 332bp [165]. E-boxes are 
specific DNA sequences of CANNG which are recognized as binding sites for 
various transcription factors. The transcription factors specifically responsible for 
transcriptional regulation are upstream stimulatory factors (USFs) and SREBP-1a 




transcription factors [161]. USF1-2 heterodimers binding to the 65bp E-box is 
necessary for insulin mediated FASN transcription however further binding of 
USF1-2 to the 332bp E-box confers full activation of the gene [166]. Additionally, 
SREBP-1a, through interactions with the SRE at the 150bp and in combination 
with USF binding the two E-boxes, can further activate FASN transcription [165].    
  
1.8 FASN Function 
 
 FASN is a key enzyme of de novo FA synthesis. FASN is crucial for the 
synthesis of palmitate, the 16 carbon long-chain saturated FA from both acetyl-
CoA and malonyl-CoA [155]. The synthesis of FAs via FASN is an exceptionally 
complicated process, which involves each of the seven enzymatic domains of the 
protein [155]. As mentioned previously, each monomer of the homodimer which 
comprises FASN can function independently and simultaneously to synthesize 
FAs [159]. Within a single monomer, the synthesis begins with the transfer of 
acetate from acetyl-CoA to the KS domain along with the transfer of malonate from 
malonyl-CoA to ACP by the MAT domain [155, 168]. The KS domain then 
catalyzes the condensation of acetate and malonate to form acetoacetyl-ACP and 
CO2 [155, 169]. Next, the acetoacetyl group is reduced by the KR domain to form 
B-hydroxyacyl-ACP which requires an NADPH molecule. The DH domain then 
catalyzes the dehydration of β-hydroxyacyl-ACP followed by another reduction by 
the ER domain, forming a saturated four carbon FA attached to ACP [155, 157, 
168, 169]. The KS domain then transfer the saturated fatty acyl from the ACP to 
itself, resulting in a net gain of two carbons to the acyl chain for each cycle of 
elongation. The now free ACP can renter the cycle, and after a total of six cycles, 
a single ACP attached to a palmitate (C:16) is synthesized. The final domain, the 
TE domain, the hydrolyzed the synthesized palmitate from the ACP, resulting in a 
free palmitic acid [155, 157, 158, 168, 169]. 
 
 Typically, FASN is found within the normal tissues of the liver and adipose, 
where more lipogenesis occurs and is expressed at relatively lower levels in most 
other normal tissues [159]. FASN can mediate energy homeostasis by 
synthesizing lipids for the purpose of storage during periods of excess food intake 
[170]. Furthermore, FASN can play an important role in membrane synthesis and 
homeostasis and thus cell division via the utilization of palmitate to form very-long-
chain FAs, which can then be utilized for the formation of glycolipids and 
sphingolipids as well as ceramides [170, 171]. 
 
 Overall, FASN functions as an important mediator of FA metabolism within 
the cell. By being a sensor to nutrient availability as well as an intermediate 
contributor of membrane synthesis, FASN is significant within several crucial 
pathways within a cell. Most importantly, FASN is an incredibly complex protein, 
consisting of several unique enzymatic domains responsible for the synthesis of 
FAs, making it a critical component of de novo FA synthesis. However, more 
research is needed to further understand the diverse set of downstream signaling 





1.9 FASN in CRC 
 
 Due to FASN’s critical role in de novo lipid synthesis in various tissues and 
since altered FA metabolism is a well-established hallmark of cancer and is 
observed in CRC, it was possible that FASN may have a role in the development 
and progression of CRC [128-130].  Indeed, it has been shown that FASN 
expression is elevated in CRC primary tumors and FASN expression is further 
elevated in later stage disease and is a poor prognostic factor for patient survival 
[153, 172]. More specifically, it has been shown that inhibition of FASN reduces 
signaling associated with CD44, a cell surface protein involved in several pathways 
including cell proliferation, migration and angiogenesis and has been implicated in 
tumor progression and metastasis of multiple cancers, including CRC [153, 173]. 
Additionally, FASN was found to directly play a role in the maintenance of energy 
homeostasis in CRC by increasing de novo lipid oxidation [154]. Also, FASN has 
been implicated in the inhibition of autophagy in CRC through the accumulation of 
p62, a substrate which is degraded during autophagy, although more investigation 
is needed to delineate a specific mechanism [154].  Furthermore, FASN has been 
shown to play an important role in CRC cell proliferation and survival in vitro via 
the regulation of the AMP-activated protein kinase (AMPK)/ mammalian target of 
rapamycin (mTOR) pathway [172]. Together, the current literature supports the 
suggestion that FASN enhances CRC progression through increased FA 
metabolism, cellular respiration and alteration of oncogenic signaling. 
 
1.9.1 FASN as a Chemotherapeutic Target in CRC 
 
 The striking upregulation of FASN in CRC and its role in CRC progression 
and poor prognosis make it a desirable target for therapeutic intervention. Multiple 
chemical inhibitors of FASN have been developed, including C75 and cerulenin 
[174-177]. C75 interacts with the KS domain of FASN and is a weak irreversible 
inhibitor [176]. Cerulenin is an antibiotic which was one of the earliest discovered 
inhibitors of FASN and interacts with the KS domain [177, 178]. Although C75 and 
cerulenin both showed promising anti-tumorigenic effects and increased cell death 
in vitro, both drugs induced significant side effects including weight loss and 
reduced nutrient consumption in mice [179]. These complications prevented these 
drugs from becoming more prominent therapeutic targets for CRC patients.  
       Another drug, which is a potent FASN inhibitor, is orlistat [180]. Orlistat is FDA-
approved for the treatment of obesity and has shown antiproliferative properties 
against prostate cancer cell lines in vitro [180]. However, antitumorigenic effects 
of orlistat were less significant in xenograft models, and the drug is poorly soluble 
and does not easily cross the cell membrane, making it a less feasible therapeutic 
for CRC [181]. The repeated failures of multiple therapeutics emphasize the need 
for novel therapeutics with the potential to successfully and safely target FASN. 
One novel chemical inhibitor which has been developed to target FASN and has 





 TVB compound have been developed by 3V-Biosciences, now known as 
Sagimet Biosciences, and is a potent reversible inhibitor of FASN [182]. TVB has 
a lower molecular weight and increased solubility compared to that of other FASN 
inhibitors mentioned above [183]. TVB acts through the reversible binding to the 
KR domain of FASN, inhibiting the first reduction of the acetoacetyl-ACP during 
FA synthesis [184].There are several analogs of TVB: TVB-2640 is used for clinical 
trials and their analogs TVB-3166 and TVB-3664 are used for pre-clinical studies 
in vitro and in vivo [185]. TVB-3166 has shown anticancer effects on oral 
squamous cell carcinoma cell lines as well as cell lines derived from lung, ovarian, 
breast, pancreatic, prostate, and hematopoietic cancers [184, 186]. In relation to 
CRC, TVB-3664 has demonstrated impressive anti-tumor activity and significant 
reduction of CRC established and primary cell line proliferation in vitro [185]. 
Increased expression of FASN was indicative of increased sensitivity to TVB-3664 
in vitro [185]. Furthermore, the effect of TVB-3664 on CRC tumor growth in vivo 
was studied using patient derived xenografts (PDXs). PDX models are useful tools 
for preclinical drug evaluations because PDX tumors retain much of their parental 
host properties when implanted into mice, including their microenvironment and 
heterogeneity [187-190]. When various CRC PDX models, which tested positive 
for FASN expression, were analyzed for TVB sensitivity in vivo, 30% of PDXs 
responded positively, with up to 50% reduction in tumor weight [185]. However, 
40% of PDXs treated had little to no response to TVB-3664 treatment, and two of 
the PDX models exhibited a negative response to TVB-3664 [185]. This then 
suggests that FASN expression alone is not sufficient to predict sensitivity to TVB 
treatment in vivo. 
 
 To further emphasize the clinical significance of targeting de novo FA 
synthesis using TVB, currently there are multiple Phase I/II clinical trials open using 
TVB analogs [191-193]. These include studies in lung and breast cancer as well 
as CRC [191-193]. Currently, TVB is in a Phase I clinical trial for CRC and it is yet 
to be seen how patient tumors respond to treatment [192]. However, with pre-
clinical indications that not all patients will respond positively to TVB treatment 
alone, an investigation into potential alternative pathways which may contribute to 
TVB resistance is needed [185]. Due to FASN’s critical role in de novo FA 
synthesis and FA metabolism, other proteins involved in FA metabolism maybe be 
suitable targets, such as those involved in the uptake of exogenous FAs, including 
CD36.  
 
1.10 CD36 Structure and Regulation 
 
 CD36 is a 53kd transmembrane protein, which contains two intracellular 
domains, one at both the C and N-terminus, as well as two transmembrane 
domains, and one extracellular domain [194]. The N-terminal half of the protein is 
where the binding domains of CD36 exist. These binding domains are responsible 
for the binding of multiple ligands including thrombospondin, oxidized LDLs (ox-




domain facilitates lipid binding, and the C-terminus can associate with Src-tyrosine 
kinases (Figure 1.2). 
  
The exact full structure of CD36 has yet to be fully delineated; however, 
several models have predicted the structure of CD36 with greater than 90% 
confidence [196, 197]. There is particular emphasis on modeling and identifying 
the exact structures involved in the FA binding pocket of CD36. A lysine residue at 
the 164 amino acid position (Lys-164) was found to be critical for FA binding [198]. 
It is suggested that this binding to Lys-164 by the FA further confers a 
conformational change within CD36 that facilitates cellular uptake [194, 199]. 
 
CD36 contains a central tunnel which traverses the entire length of the 
protein [194]. Models show that the FA binding pocket contains a groove which 
leads directly into the central tunnel of CD36 [194]. It is suggested that FA binding 
to Lys-164 in the binding pocket could displace a glutamate 335 residue at the top 
of the tunnel, allowing the FA access to the tunnel [198]. It was also discovered 
that the tunnel has an exterior entry point on the surface of CD36, separate from 
that of the FA binding pocket [198]. Free access to the tunnel by a FA may be 
restricted due to an acetylated Lys-231 residue at the tunnel entrance [198]. 
However, further studies beyond modeling are required to fully realize CD36’s 
structure, particularly those structures of the FA binding pocket and the central 
tunnel. 
 
The promoter region of CD36 contains peroxisome proliferator-activated 
receptor (PPAR) response elements (PPREs), and therefore PPARγ can regulate 
the mRNA transcription after binding to its ligands, of which include ox-LDLs and 
some prostaglandins [200]. Specifically, a positive feedback loop has been 
described in macrophages, where ox-LDLs absorbed by CD36 further active PPAR 
signaling through the mitogen-activated protein kinase (MAPK) signaling cascade, 
and thus increasing transcription of CD36, and in return further increasing ox-LDL 
uptake, leading to foam cell formation [201]. In addition to the PPREs, an 
interferon-γ-activated sequence (GAS) was also identified in the promoter region 
of CD36, of which can be bound by signal transducer and activator of transcription 
3 (STAT3). Binding of STAT3 to this GAS region in response to several Janus 
kinase (JAK) ligands, such as epidermal growth factor (EGF), and promotes CD36 
transcription [202]. 
 
CD36 is heavily post-translationally modified with modifications including 
phosphorylation, glycosylation, palmitoylation, acetylation and ubiquitination [194]. 
These modifications create a protein with a mass of approximately 88kD 
[203].Trafficking of the protein and membrane localization is heavily regulated. 
Specifically, there are two palmitoylation sites at each of the termini which are 
necessary for membrane localization. Furthermore, CD36 consists of several 
disulfide bridges within the carboxyl terminal half, which are also important for 
membrane association [194]. Moreover, CD36 contains nine extracellular sites 




417) [204]. Glycosylation at each of these sites was shown to be critical for overall 
protein folding as well as cellular trafficking of the protein to the cell membrane 
[204].  
 
CD36 may also be regulated based on fatty acid uptake and diet [194, 205]. 
A separate lysine residue within the FA binding pocket, Lys-166, was found to be 
acetylated which increases the hydrophobicity of the pocket, which is suggested 
in the regulation of FA access to the binding pocket or assist in the orientation of 
the FA once within the pocket [194]. Furthermore, CD36 may be nutritionally 
regulated via ubiquitination at two lysine residues within the C-terminus, which is 
upregulated with increased FFA availability and decreased with insulin treatment, 
suggesting a negative feedback loop during increased FFA availability [205]. 
  
1.11 CD36 Function 
 
 CD36 is expressed in various tissues throughout the body and is enriched 
in tissues of the circulatory system, immune cells, and particularly expressed in 
adipose tissues [206]. CD36 is also basally expressed at relatively lower levels in 
tissues of the digestive tract, particularly the small intestine and colon [206]. CD36 
is a multifunctional glycoprotein and is a receptor for several ligands including 
thrombospondin (TSP-1), ox-LDLs and FAs and based on the tissues where CD36 
is expressed, its function may be significantly different [207]. 
 
 CD36 was first described as a receptor for TSP-1 and binding of TSP-1 by 
CD36 has been shown to regulate several cellular functions including the negative 
regulation of angiogenesis in ovarian tissues [208]. Furthermore, CD36 has been 
shown to facilitate the interaction between Src-homology-2-domain-containing 
protein tyrosine phosphatase (SHP-1) with vascular endothelial growth factor 
receptor 2 (VEGFR2) and, thus, reducing vascular endothelia growth factor 
signaling (VEGF) in endothelial cells [209]. CD36 binding to TSP-1 on the surface 
of platelets results in a hyperactive platelet state and promotes thrombosis [210]. 
CD36 can also facilitate intracellular signaling through other Src-tyrosine kinases 
in pathways including inflammation and atherosclerosis [210]. 
 
Aside from thrombospondin binding, more recently it has become well 
established that one of the major functions of CD36 is the binding and uptake of 
ox-LDLs and long-chain and very-long chain FAs [194, 211-213]. Interestingly, it 
was found that both FAs and ox-LDLs share the same binding position within the 
FA binding pocket, which include both the Lys-164 and Lys-166 residues [214]. 
The major areas of study delineating CD36’s function in the binding of ox-LDLs 
involve its role in the progression of atherosclerosis [215]. Ox-LDLs are now 
recognized as a marker for inflammation and atherosclerosis, and CD36 mediated 
uptake of ox-LDLs has been directly linked to chronic inflammation and 
atherosclerosis [215]. More specifically, interactions between CD36 and ox-LDL 




which activate nuclear factor kB (NF-kB) signaling and increased inflammation 
[216]. 
 
CD36 is highly expressed in adipose tissues and regulates lipid storage and 
lipolysis and in the presence of insulin, facilitates uptake of FAs [203, 215]. It was 
shown that the carboxyl group of a FA interacts directly with the Lys-164 at the 
entry position to the FA binding pocket, suggesting the Lys-164 aides in the proper 
positioning of the FA, orienting the long acyl chain of the FA so that it enters the 
pocket first [198]. Although the FA binding pocket is critical for the binding of FAs, 
it alone is not sufficient for full transfer of the FA into the cell. The central tunnel, 
which traverses the entire length of the protein, is connected to the FA binding 
pocket via a groove and is also critical for FA uptake as it is through this tunnel 
that FAs move through CD36 and to the cell membrane [194]. FAs bound and 
transported across the cell membrane by CD36 can then be used for a variety of 
purposes as described above, include as an energy source or substrates for 
membrane synthesis [215]. 
 
1.12 CD36 in Cancer 
  
Due to the important role CD36 plays in the uptake of extracellular FAs, and 
the fact that dysregulated FA metabolism is a hallmark of cancer, it is possible that 
CD36 may play a role in the progression of CRC. CD36 has been shown to 
contribute to the progression and metastasis of hepatocellular and oral carcinoma, 
as well as glioblastoma, prostate, cervical, breast and ovarian cancers [149-152, 
217-221].  
 
In hepatocellular carcinoma (HCC), CD36 was shown to be significantly 
upregulated in patient tissues and established HCC cell lines [221, 222]. 
Furthermore, CD36 expression increased HCC cell proliferation, migration, and 
invasion in vitro as well as the promotion of tumor growth and metastasis in vivo 
[221]. Additionally, it was shown that CD36 promotes the progression of HCC by 
activating glycolysis through the upregulation of the Src/PI3K/AKT/mTOR 
signaling pathway [221]. Furthermore, it has also been shown that CD36 
contributes significantly to epithelial to mesenchymal transition (EMT) in HCC via 
CD36 mediated FA uptake [222]. It was suggested that CD36 promotes this EMT 
in HCC through increased Wnt-TGFβ signaling; however more investigation is 
needed to fully discern the mechanisms behind CD36 -driven EMT [222]. 
 
As mentioned, aside from HCC, CD36 has also been shown to promote 
glioblastoma (GBM) progression [149]. Specifically, CD36 is highly upregulated in 
GBM cells and is enriched further in GBM cancer stem cells (CSCs) [149]. 
Furthermore, reduced expression of CD36 significantly inhibited the self-renewal 
and tumorigenic properties of GBM CSCs. Additionally, treatment of GBM CSCs 
with ox-LDLS enhanced cell proliferation [149]. Lastly, the expression of CD36 in 
GBM patients correlated with a poor prognosis [149]. However, exact mechanistic 





CD36 has also been shown to promote the progression of ovarian, cervical 
and breast cancers [151, 218-220]. In ovarian cancer, it was shown that CD36 
promotes an adipocyte-driven phenotype in ovarian cancer cells in a FA uptake 
dependent manner [151]. Additionally, inhibition or knockdown of CD36 completely 
attenuates this adipocyte dependent malignant phenotype as well as reduces cell 
adhesion, invasion, and migration in vitro [151]. Furthermore, human metastatic 
ovarian tumors exhibit an upregulation of CD36 expression and inhibition of CD36 
via a neutralizing antibody reduced tumor burden in vivo [151].  
 
CD36 is also highly expressed in cervical cancer tissues and data suggests 
that CD36 promotes cervical cancer cell proliferation, migration, and invasion both 
in vitro and in vivo [220]. Interestingly, TGFβ treatment of cervical cancer cells 
increased CD36 expression and downregulated the expression of e-cadherin, a 
crucial marker of EMT in several cancers [223]. Additionally, CD36 was also found 
to promote breast cancer progression and metastasis and is a poor prognostic 
factor for breast cancer patient survival [218, 219]. More specifically, breast cancer 
cell proliferation, which is enhanced via exogenous FA treatment, is significantly 
reduced in CD36 knockdown breast cancer cell lines [219]. FA treatment of these 
CD36 knockdown cell lines did not restore the more proliferative phenotype, 
suggesting that CD36 plays a significant role in breast cancer cell proliferation in 
a FA uptake dependent manner [219]. Furthermore, CD36 expression is higher in 
estrogen receptor rich (ER-rich) cell lines compare to ER-negative cells [218]. 
Specifically, CD36 promotes the expression of estrogen receptor alpha (ERα), 
which can be responsible for increased cell proliferation and apoptosis inhibition, 
as well as ERK1/2, which promotes breast cancer cell proliferation and invasion 
[224, 225]. Lastly, it was reported that CD36 contributes significantly to metastasis 
in oral carcinoma. CD36 high expressing oral carcinoma cells were shown to 
promote migration, invasion, and colony formation in vitro [150]. Furthermore, 
CD36 high expressing cells were shown to be unique in their ability to initiate 
metastasis in orthotopic oral carcinoma xenografts in vivo [150]. Inhibition of CD36 
via treatment with a neutralizing antibody completely abolished local invasion and 
metastasis of oral carcinoma tumors in vivo [150]. Interestingly, inhibition and 
knockdown of CD36 appeared to have no significant effect on primary oral 
carcinoma tumor growth, and only attenuated metastatic disease [150].  
 
Together, these data suggest that CD36 plays an important role in the 
progression and metastasis of many cancers. However, further investigation is 
critical to understand the mechanistic pathways involving CD36’s pro tumorigenic 
and metastatic characteristics. Moreover, no previous studies have investigated 
the relationship of CD36 driven FA metabolism and that of de novo FA synthesis.  
 
1.12.1 CD36 as a Chemotherapeutic Target 
 
 CD36 has been the subject of a few pre-clinical and phase I/II clinical trials 




Interestingly, each of these clinical trials have targeted CD36 from the perspective 
of its binding to TSP-1 [226]. Due to previous data suggesting that binding of TSP-
1 by CD36 may upregulate anti-angiogenesis, these multiple clinical trials involved 
TSP-1 mimetic peptides, which further enhance TSP-1-CD36 downstream 
signaling as described previously [208, 209, 226]. These drugs include ABT-510, 
ABT526, and ABT-898 as well as CVX-22, and CVX-045 [227, 228]. The ABT 
drugs showed promise in pre-clinical in vivo studies but failed in phase II clinical 
trials after results showed the drug had no significant effect on tumor progression 
and patients displayed severe side effects [228]. Likewise, the CVX drugs showed 
significant tumor regression in animal studies, but did not make it past phase I 
clinical trials due to adverse side effects and poor response rates [227]. However, 
no such clinical trials targeting CD36 in CRC have previously been explored. 
 
 Due to the poor efficacy of targeting CD36 via TSP-1 binding, alternate 
pathways in which CD36 is involved may be more viable. Since recent studies 
have established CD36 as a prominent FA transporter, and since altered FA 
metabolism is a hallmark of cancer, targeting the FA transport function of CD36 
could be a possible therapeutic strategy [128, 194, 229]. Furthermore, more 
investigation into the relationship between CD36 mediated FA uptake and de novo 
FA synthesis may yield more potential therapeutic modalities for the treatment of 




 The purpose of this project was to understand whether CD36 contributes to 
CRC progression and metastasis as well as what relationship CD36 may have with 
de novo FA synthesis. The hypothesis is that: (1) Inhibition of FASN via TVB 
inhibitors upregulates CD36 and, thus, exogenous FA uptake, (2) CD36 
upregulation promotes CRC primary tumor proliferation and survival, and (3) CD36 
































































Colon Cancer Stage 5-Year Survival Rate 
Stage I 92% 
Stage IIA 87% 
Stage IIB 63% 
Stage IIIA 83% 
Stage IIIB 64% 
Stage IIIC 44% 


































Figure 1.1 Diagram of cellular FA acquisition. Cell can uptake exogenous FAs 
through FA transporters which include the FABPs, FATPs, and CD36 or they can 























Figure 1.2 Structure of CD36. Schematic showing the various post translational 























CHAPTER 2. INHIBITION OF FATTY ACID SYNTHASE UPREGULATES 





Purpose: Altered FA metabolism is a hallmark of cancer and a potential 
target for cancer therapy. FA Translocase (CD36) has an important role in FA 
metabolism as a FA transporter. FA Synthase (FASN), a key enzyme of de novo 
lipogenesis, is associated with poorer prognosis in many cancers including 
colorectal cancer (CRC). However, the role of CD36 in CRC as well as its relation 
to FA synthesis is not understood. The purpose of our study was to: (i) determine 
the functional importance of CD36 in CRC and (ii) investigate the interconnection 
between CD36 and FASN expression in CRC cells. 
 
Methods: CD36 and FASN expression was assessed in a CRC tumor 
microarray (matched normal colon and primary tumor; 56 cases) as well as 
matched normal colon, primary and metastatic tumors by immunohistochemistry. 
Cellular proliferation was assessed in control and CD36 shRNA knockdown CRC 
cells and in primary CRC cells established from patient-derived xenografts treated 
with Sulfo-N-succinimidyl oleate (SSO), a CD36 inhibitor, and TVB-3664, a FASN 
inhibitor currently in clinical trial. The effect of CD36 knockdown on tumor growth 
was assessed in vitro using a colony formation assay and in vivo using a 
subcutaneous xenograft model. Expression of pro-survival and apoptotic markers 
was assessed in CD36 knockdown and overexpression CRC cells and in Pt 2402 
CD36high and CD36low isogenic cells via western blot. CD36 localization was 
assessed via confocal imaging. Effect of FASN knockout on CD36 expression in a 
genetically modified mouse model was assessed via qRT-PCR and western blot. 
 
Results: CD36 is overexpressed in CRC primary tumors compared to 
normal colon mucosa. Pharmacological inhibition of FASN and shRNA-mediated 
knockdown of FASN specifically induces CD36 expression and its translocation to 
the plasma membrane in CRC cells and human tissues. Furthermore, deletion of 
FASN in APC/Cre mice significantly increases CD36 mRNA and protein 
expression. Additionally, knockdown of FASN increase extracellular FA uptake in 
a CD36 dependent manner. Cellular proliferation is significantly reduced when 
CD36 is inhibited by SSO. Inhibition of CD36 reduces CRC cell proliferation and 
colony formation in vitro. Knockdown and chemical inhibition of CD36 decreased 
expression of survivin, which has been shown to promote cancer cell survival in 
many tumor types. Overexpression of CD36 increased survivin expression in CRC 
cells. A higher level of survivin was observed in Pt 2402 CD36high cells as 
compared to Pt2402 CD36low cells. Knockdown and pharmacological inhibition of 
CD36 significantly reduces the ability of CRC cells to form xenograft tumors in vivo. 
Further reduction on CRC cell proliferation in vitro is observed when SSO 





Conclusions: This study for the first time demonstrates that inhibition of 
FASN selectively upregulates CD36 in multiple colorectal cancer models including 
human tissues, colorectal cancer cells with shRNA mediated knockdown of FA 
synthase and genetically modified mouse tissues with heterozygous and 
homozygous deletion of FASN. In summary, our study suggests that upregulation 
of CD36 expression is a potential compensatory mechanism for FASN inhibition 




 Colorectal cancer (CRC) is the leading cause of non-smoking related 
cancer deaths in the world [1]. Altered FA metabolism is a hallmark of cancer and 
a potential target for therapeutic intervention [128-130]. FA Synthase (FASN), a 
key enzyme of de novo lipogenesis, is significantly upregulated in CRC and 
promotes tumor growth and metastasis [153, 230, 231]. Novel FASN inhibitors 
developed by Sagimet Biosciences show anti-cancer activity in lung, prostate, 
ovarian and colon cancer models in vitro and in vivo [185, 232, 233], and are 
currently being tested in phase I/II clinical trials [234-236]. Our studies show anti-
tumor activity of TVB inhibitors in primary CRC cells and CRC patient-derived 
xenograft (PDX) models [185, 237]. 
 
While most tumors exhibit a shift toward FA synthesis, they can also 
scavenge lipids from their environment [130]. FA Translocase (CD36), a 
multifunctional glycoprotein, has an important role in FA metabolism as a FA 
receptor and transporter [194, 238]. CD36 translocate to the plasma membrane, 
where an extracellular domain of the protein binds low density lipoproteins and 
transports them across the plasma membrane into the cytosol, thus playing a 
critical role in the metabolism of extracellular FAs [194, 238, 239]. CD36 is subject 
to various types of post-translational modifications. Glycosylation, ubiquitination 
and palmitoylation are involved in regulating CD36 stability and the rate of FA 
uptake [240]. Recent studies have shown that CD36 is highly expressed and 
enhances the progression of solid malignancies such as breast, ovarian, gastric, 
and glioblastoma cancers [149, 151, 241, 242]. Silencing CD36 in human prostate 
cancer cells reduces FA uptake and cellular proliferation [243]. Furthermore, the 
presence of CD36 positive, metastasis initiating cells correlates with a poorer 
prognosis in glioblastoma and oral carcinoma [149, 150]. The contribution of CD36 
to CRC progression has not yet been investigated. 
 
Since cancer cells utilize both endogenously-synthesized lipids and 
exogeneous FAs [244], and our published data indicate that an enhanced uptake 
of dietary FAs may be a potential mechanism of resistance to FASN inhibitors 
[185], the goal of this study was to evaluate the interconnection between these two 
pathways.  
 
We found that CD36 is significantly overexpressed in CRC and that there is 




specimens. We demonstrate that a decrease in FASN expression is associated 
with selective induction of CD36 and that this phenomenon is consistent among 
multiple cancer models. Pharmacological and shRNA-mediated inhibition of CD36 
decreases proliferation of primary CRC cells in vitro and inhibits tumor growth in 
vivo. We also show that CD36 overexpression is associated with upregulation of 
survivin, a protein linked to apoptosis resistance, metastasis, bypass of cell cycle 
checkpoints, and resistance to therapy [245, 246]. Consistent with our in vitro data, 
we show that CD36high-expressing cells, isolated from CRC PDXs, have a 
significantly higher level of survivin as compared to CD36low-expressing cells from 
the same tumor. Our results also demonstrate that combined inhibition of FASN 
and CD36 has a synergetic effect on inhibition of cellular proliferation suggesting 
that combination treatment may be a potential therapeutic strategy for CRC. 
  
Together, our findings demonstrate the tightly regulated interconnection 
between de novo lipid synthesis and CD36-mediated lipid uptake in CRC 
progression during targeted inhibition of FASN, suggesting that inhibition of CD36 




2.3.1 CD36 Protein is Overexpressed in CRC  
 
  Upregulation of lipid metabolism is a common characteristic of many solid 
malignancies, and frequently, enhanced de novo lipogenesis occurs concomitantly 
with enhanced import of lipids from the extracellular space [129, 247]. In our 
previously published study we showed that FASN is significantly overexpressed in 
primary tumor tissues as compared to matched normal colon mucosa using tissue 
microarray analysis (TMA) [248]. Using the same TMA, we assessed the 
expression of CD36 levels in tumor tissues and found that expression was 
significantly higher compared to normal colon mucosa as determined by statistical 
evaluation of immunoreactivity scores. We noted that the expression of CD36 is 
predominantly cytosolic in primary CRC tumors (Figure 2.1 A-B). Interestingly, 
statistical analysis via Spearman Correlation showed a positive correlation 
between expression of CD36 and FASN in primary CRC tumor tissues, but it was 
not statistically significant (Spearman r =0.21743, n = 56). We have also detected 
an increase in expression of CD36 in CRC metastasis to liver and lung (Figure 2.1 
C). 
  
Using the Cancer Genome Atlas (TCGA) , we also analyzed FASN and 
CD36 mRNA expression. Consistent with protein data, the level of FASN mRNA is 
significantly higher in tumor tissues as compared to normal mucosa 
(Supplementary Figure S2.1 A). In contrast, we found that the level of CD36 
mRNA is significantly lower in cancer tissues as compared to normal tissues 
(Supplementary Figure S2.1 B). Interestingly, according to data analysis from the 
Human Protein Atlas, the high mRNA expression of CD36 (n = 131) is associated 




5-year survival of 64 % patients with low CD36 mRNA expression (n = 466) 
(https://www.proteinatlas.org/ENSG00000135218-
CD36/pathology/colorectal+cancer).  Statistical analysis of correlation between 
FASN and CD36 revealed a significant negative correlation between FASN and 
CD36 mRNA levels in tumor tissues, but not in normal tissues (Figure 2.1 D). 
 
To further delineate association between expression of FASN and CD36, 
we analyzed expression of these proteins in fresh human normal colon mucosa, 
primary CRC tissues and metastasis (Figure 2.1 E-F). The predicted molecular 
mass of CD36 protein is 53kD. However, due to the post-transcriptional 
modifications including extensive protein glycosylation, it is widely reported as 
approximately 80- 88kD protein [238, 240, 249]. This 80-88kD size will be shown 
for all in vitro and in vivo data figures of this manuscript. In the analyzed tissues 
sample set, the expression of FASN is higher in primary tumors as compared to 
normal mucosa in most cases. Due to FASN being expressed in healthy liver 
tissue, it is not surprising to see that its expression is higher in the normal liver as 
compared to liver metastasis. CD36 expression seems to be higher or the same in 
primary tumors as compared to normal colon mucosa. However, expression of 
CD36, particularly its glycosylated form, is much higher in liver metastasis as 
compared to normal liver or normal colon mucosa (Figure 2.1 E).  
 
To further analyze CD36 in colorectal cancer we used several PDX models, 
which retain the intratumorally clonal heterogeneity and tumor microenvironment 
of the parent tumor through passages in mice [185, 250]. We analyzed the 
expression of CD36 in nine PDXs established from primary tumors and CRC 
metastasis [185], and found that CD36 (88kD) is mostly associated with PDX 
established from metastatic tumors with an exception of Pt 2568 which was 
established from primary CRC tumor [185] (Supplementary Figure S2.1 C). 
Together, these data demonstrate that CD36 is upregulated and exhibit multiple 
post-translational modifications in CRC and that there is a significant inverse 
correlation between mRNA expression of FASN and CD36 in primary human CRC.  
 
2.3.2 FASN Selectively Regulates Expression of CD36 
 
 To test whether alterations in FASN expression affect FA uptake, we 
assessed the expression of major FA transporters (FATPs and CD36) in HCT116 
NTC and FASN shRNA CRC cells and found that FASN selectively upregulates 
mRNA expression of CD36, but not other FAs transporters (Figure 2.2 A). To 
confirm that FASN selectively upregulates CD36, we treated fresh CRC human 
tissue slices with TVB-3664 and assessed the expression of FA transporters, 
including CD36. Consistent with our in vitro data, in all three CRC cases 
(Supplementary Table S2.1), we observed that CD36 mRNA expression 
increased at least two-fold and as much as four-fold when tissues were treated 
with TVB-3664. No changes were observed in expression of the other FA 





To further elucidate whether the level of endogenous FA synthesis affects 
the expression of CD36, we next treated primary CRC cells from Pt 93 and Pt 130 
with TVB-3664 for six days at a concentration of 0.2μM as previously described 
[185]. Inhibition of FASN led to an increase in CD36 mRNA and protein expression 
in both cell lines (Figure 2.2 C). Consistently, shRNA-mediated knockdown of 
FASN in HCT116 and HT29 cell lines led to an increase in CD36 expression in 
normal and hypoxic conditions in both cell lines (Figure 2.2 D, Supplementary 
Figure S2.2 A). Interestingly, shRNA-mediated knockdown of CD36 does not 
affect FASN expression, suggesting a one-dimensional relationship between the 
two proteins (Supplementary Figure S2.2 B). 
 
The adenomatous polyposis coli (APC) gene product is mutated in the vast 
majority of human CRC and deletion of the APC gene leads to intestinal tumor 
formation in mice [251]. In agreement with in vitro data, the analysis of intestinal 
tumors from mice with hetero- and homozygous deletions of FASN on C57BL/6-
Apc/Cre background showed that deletion of FASN significantly upregulates CD36 
expression (Figure 2.2 E-F). Collectively, these data suggest that inhibition of 
FASN leads to selective upregulation of CD36 expression. 
 
2.3.3 Inhibition of FASN Leads to CD36 Translocation to Plasma Membrane 
 
 Confocal imaging of primary Pt 93 CRC cells, control and treated with TVB-
3664, shows that CD36 protein expression is upregulated and primarily localized 
to the plasma membrane when FASN is inhibited by TVB-3664 (Figure 2.2 G). To 
confirm these data, primary CRC cells from Pt 93 and Pt 130 were treated with 
0.2 μM TVB-3664 for six days in normal or serum-starved conditions and labeled 
with CD36-FITC antibody. Flow cytometry analysis was performed; the results 
confirmed that inhibition of FASN activity by TVB-3664 led to an increase in 
membrane-associated CD36 when compared to control cells in both cell lines in 
normal and serum-starved conditions (Figure 2.2 H). 
  
To test whether this upregulation and translocation of CD36 to the plasma 
membrane was related to FA metabolism, a FA uptake assay was performed. 
HCT116, NTC and FASN shRNA cells were plated and treated with BODIPY FL 
and imaged using confocal microscopy. We observed that FASN knockdown 
increases FA uptake as indicated by an increase in BODIPY FL staining (Figure 
2.2 I). Furthermore, to test that this increase in FAs within the cell was due to CD36 
upregulation, we treated NTC and FASN shRNA cells with neutralizing antibody 
for CD36. Blocking CD36 has a minimum effect in NTC cells, but significantly 
decreases BODIPY FL uptake in FASN shRNA cells, further confirming that 
inhibition of FASN increases FA uptake via upregulation of CD36 (Figure 2.2 I).   
 
2.3.4 Inhibition of CD36 reduces CRC Cell Proliferation in vitro 
 
 We have previously shown that stable knockdown and pharmacological 




tumor growth [153, 185]. However, the observed effects in vivo were not as 
prominent as the effects in vitro, suggesting the potential compensatory effects of 
diet and exogeneous FA uptake on tumor growth [153, 185]. To test whether 
blocking fatty-acid uptake via CD36 has an effect on CRC cell proliferation, primary 
CRC cells, Pt 93 and Pt 130, were treated with the chemical CD36 inhibitor 
sulfosuccinimidyl oleate (SSO), which binds to CD36 via Lys164 in the 
hydrophobic cavity thereby impairing CD36-mediated FA uptake [240, 252], at 
100μM in both normal and serum free medium (SFM) conditions. Under both 
conditions, primary CRC cells treated with SSO exhibited decreased cellular 
proliferation. Interestingly, sensitivity of both cell lines to SSO increased in SFM 
(Figure 2.3 A). To evaluate differences in CD36 expression in normal and SFM, 
we performed confocal microscopy on Pt 93 cells cultured in normal and SFM 
conditions. We found that starvation of CRC cells leads to upregulation of CD36, 
which could explain an increase in sensitivity to SSO treatment (Figure 2.3 B).  
 
To assess the effect of CD36 overexpression on apoptotic markers we 
performed an Apoptosis Antibody Array. Data showed that overexpression of 
CD36 decreased caspase-3 cleavage and increased expression of survivin, a 
protein overexpressed in most transformed cell lines and malignancies and 
associated with poor clinical outcome (Supplementary Figure S2.3 A) [246, 253]. 
Consistently, western blot analysis of control and SSO-treated Pt 130 and Pt 93 
primary CRC cells showed an increase in cleaved caspase-3 in both cell lines. A 
decrease in expression of survivin was observed in Pt 130 cells only 
(Supplementary Figure S2.3 B). Consistent with pharmacological inhibition of 
CD36, shRNA-mediated knockdown of CD36 lead to a significant decrease in 
cellular proliferation and expression of survivin and pAkt in HCT116 cells (Figure 
2.3 C-E). Furthermore, shRNA-mediated knockdown of CD36 inhibits colony 
formation in the HT29 cell line (Supplementary Figure S2.3 C). Together, these 
data demonstrate that CD36 promotes cellular proliferation in CRC. 
 
2.3.5 Inhibition and Knockdown of CD36 Reduces Xenograft Tumor Growth in vivo 
 
 To further investigate the role of CD36 in CRC tumor growth, HCT116 
subcutaneous xenografts were treated with vehicle or SSO daily for 5 weeks. SSO 
treatment lead to significant decreases in tumor volume compared to vehicle 
control with no observable SSO toxicity as indicated by unchanged animal weight 
(Figure 24 A). Furthermore, consistent with in vitro data, analysis of tumor tissues 
treated with SSO show a decrease in survivin mRNA (Figure 2.4 B). FASN mRNA 
expression does not change with inhibition of CD36, further supporting the notion 
of a one directional relationship between the two proteins. Interestingly, SSO 
treatment led to an increase in CD36 mRNA suggesting that the potential 
compensation for the lack of functional CD36 was due to antagonistic action of 
SSO (Figure 2.4 B).  
 
To further elucidate the role of CD36 in CRC tumor growth, the CRC cell 




efficiently metastasize to lung via in vivo selection process [254]), were established 
as subcutaneous xenografts. Interestingly, in vivo selection led to an increase in 
CD36 expression in HT29 LuM3 as compared to parental HT29 cells 
(Supplementary Figure S2.4 A). HCT116, HT29 and HT29 LuM3 cells (NTC and 
shRNA mediated CD36 knockdown cell lines) were injected subcutaneously into 
Nu/Nu mice and tumor growth was measured. Knockdown of CD36 in HCT116 
cells markedly attenuated the growth of xenograft tumors compared to NTC 
(Figure 2.4 C, Supplementary S2.4 B). In the case of CD36 shRNA #2 and CD36 
shRNA #4 cells, we were able to identify microtumors at the site of injections. 
Tumor tissues were stained for Ki67, a known marker for tumor cell proliferation 
and growth [255]. Ki67 expression was greatly reduced in CD36 knockdown 
tumors as compared to control (Figure 2.4 D). In contrast to HCT116 cells, CD36 
knockdown in HT29 did not significantly affect tumor growth, suggesting that this 
cell line may not be dependent on CD36 due to considerably lower CD36 
expression as compared to HCT116 cells (Supplementary Figure S2.4 A, C, D). 
However, CD36 knockdown using CD36 shRNA #4 in HT29 LuM3 cells, which 
have higher levels of CD36 expression as well as higher metastatic potential [254] 
(Supplementary Figure S2.4 A), lead to a more prominent inhibition of tumor 
growth and a decrease in tumor weight (Figure 2.4 E). Moreover, consistent with 
our in vitro data, qRT-PCR analysis of tumor tissues demonstrates a decrease in 
survivin expression when CD36 is knocked down in HT29 LuM3 tumors (Figure 
2.4 F). Thus, these data further support the role of CD36 in promoting CRC tumor 
growth. 
 
2.3.6 High Expression of CD36 is Associated with an Increase in Survivin in CRC 
 
 To further establish that CD36 promotes cellular proliferation via 
upregulation of pro-survival pathways, we utilized a PDX tumor model, Pt 2402, 
which was established from a CRC metastasis to the lung [185] and is positive for 
CD36 expression (see Figure 2.1 E). Tumor tissue from 1st generation Pt 2402 
PDX was inoculated into NOD/SCID mice and grown to approximately 1cm3 
volume. The tumor was excised, digested as previously described to a single cell 
suspension [248], stained with CD36-FITC and sorted via flow cytometry. The top 
10% of the brightest green fluorescent protein (GFP) positive cells (117,000 cells), 
designated CD36high, and the bottom 10% of GFP negative cells (3,120,000 cells), 
designated CD36low, were sorted separately, placed in Matrigel, and sequentially 
implanted into NOD/SCID mice and allowed to grow. The tumor established from 
CD36high cells grew much larger compared to the CD36low tumor (tumor volume 
2419.64mm3 versus 53.57mm3, respectively) (Figure 2.5 A-B). Western blot 
analysis of tumor tissues from CD36high and CD36low cells showed an increase in 
survivin expression in the CD36high tumors in comparison to the CD36low tumors 
(Figure 2.5 C). Interestingly, similar to our data obtained from TMA analysis, we 
observed that FASN was higher in CD36high cells as compared to CD36low cells, 
further supporting a potential interconnection between these two proteins (Figure 




reduction in Ki67 expression in the CD36low tumors compared to CD36high (Figure 
2.5 D). 
  
To confirm that an increase in CD36 expression is associated with an 
increase in survivin expression, we overexpressed CD36 in the established 
HCT116 CRC cell line. Western blot analysis of HCT116 cells demonstrated CD36 
overexpression leads to an increase in expression of survivin and activation of Akt, 
an upstream translational regulator of surviving in CRC [256], as well as a 
decrease in cleaved-PARP (Figure 2.5 E). Therefore, taken together, our data 
suggest that upregulation of pAkt and survivin are potential mechanisms by which 
CD36 promotes CRC cell proliferation and tumor growth. 
 
2.3.7 Inhibition of FASN and CD36 in Combination Reduce Primary CRC 
Proliferation in vitro 
 
 Both de novo synthesized and exogenous FA play important roles in 
carcinogenesis [247, 257], To extend our findings that FASN inhibition upregulates 
the expression of CD36 and to further test whether inhibition of CD36 can improve 
the efficacy of TVB-3664, primary CRC cells from Pt 93 and Pt 130 were treated 
with CD36 inhibitor SSO and FASN inhibitor TVB-3664, alone or in combination, 
in both normal and serum-starved media. Cellular proliferation was significantly 
reduced in both SSO- and TVB-3664-treated cells and was further significantly 
reduced in cells that received combination treatment (Figure 2.6 A). Western blot 
analysis of CRC cells treated with a combination of TVB-3664 and SSO shows 
that combination treatment significantly reduces expression of survivin in PT130 
and HCT116 cell lines but not in Pt93 cell line as compared to control or single 
agent treatment alone (Figure 2.6 B). Combination treatment was also associated 
with reduced expression of cyclin D1 in Pt93 and HCT116 cell lines. Interestingly, 
cyclin D1 in Pt130 cells increased expression in combination treatments. This 
suggests a different mode of action and sensitivity to SSO and TVB-3664 in Pt130 
when compared to other CRC cell lines. Collectively, these data suggest that 
inhibition of both FA synthesis and FA uptake may be a potential therapeutic 
strategy for CRC. However, further studies are necessary to evaluate the effect of 






 Our previous studies demonstrate that the effect of FASN inhibition on 
cellular proliferation in vitro does not always translate to the same effect on tumor 
growth in vivo [153, 185]. Despite a significant decrease in cellular proliferation in 
primary CRC cell lines treated with TVB-3664, the efficacy of TVB-3664 in PDX 
models was much lower, suggesting a potential compensatory impact of diet on 




delineate the effect of FASN inhibition on exogeneous FA uptake and elucidate the 
effect of FA uptake on sustaining cellular proliferation.  
 
Here, for the first time, we report that inhibition of FASN leads to a selective 
upregulation of CD36 expression. CD36 enhances FA uptake and FA oxidation 
and plays a critical role in cancer cell growth and metastasis [149-151, 258, 259]. 
Consistent with reports that CD36 is upregulated in breast cancer and glioblastoma 
[260], we found that CD36 is highly expressed in CRC as compared to normal 
mucosa. Tumor stroma is deficient for CD36 expression [226]. High stromal 
content in fresh primary CRC tumors can potentially explain why fresh CRC tissue 
analysis shows inconsistent result for CD36 expression in primary CRC as 
compared to normal colon.  Interestingly, based on tissue analysis, we found that 
high expression of CD36 is primarily associated with CRC metastasis suggesting 
that metastatic tumors are more dependent on FA uptake as compared to primary 
CRC. Our findings are supported by multiple studies showing CD36 involvement 
in metastatic disease [150, 261, 262]. Interestingly, even though we have identified 
a positive correlation between the protein expression of FASN and CD36 using 
TMA analysis, based on TCGA data, there is a significant inverse correlation 
between these two proteins at the mRNA levels. Indeed, we found that inhibition 
of FASN selectively upregulates CD36 mRNA and protein expression, but not 
expression of other FA transporters in multiple models including CRC cells, tumor 
xenografts, genetically modified mice and in human tissues. Interestingly, we did 
not note any significant changes in FASN expression when the expression of CD36 
was altered, suggesting that the level of de novo lipid synthesis is not regulated by 
FA uptake via CD36 in our models. Current understanding of the regulation of 
CD36 expression is rather limited [263], and how CD36 expression is regulated in 
cancer, and in particular in CRC, is not known. Several transcriptional activators 
have been implicated in regulation of CD36 expression including peroxisome 
proliferator-activated receptors (PPARs), CCAAT/enhancer-binding protein and 
HIF-1 [238]. Ongoing studies in our laboratory are investigating CD36 expression 
in different cell types in primary and metastatic CRC and potential mechanisms of 
CD36 regulation by FASN. 
 
It has been reported that siRNA-mediated inhibition of CD36 decreases 
cellular proliferation in MCF-7 breast cancer cells [241]. Additionally, CD36 has 
pro-tumorigenic and progression properties in glioblastoma stem cells [149]. In 
agreement with these data, our study shows that chemical inhibition and stable 
knockdown of CD36 via shRNA in established and primary CRC cells decrease 
cellular proliferation. Consistent with data using a specific small molecule CD36 
inhibitor, 2-methylthio-1,4-napthoquinone (MTN), in glioblastoma stem cells [149], 
inhibition of CD36 with SSO is associated with a decrease in activation of pAkt. 
We have also showed that CD36 regulates survivin, a member of the inhibitor of 
apoptosis (IAP) family that is highly expressed in most cancer and associated with 
a poor prognosis [264]. The pro-survival role of CD36 in CRC is further supported 




establish xenograft tumors, which grow significantly faster and express higher 
levels of survivin, in comparison to CD36low cells.  
 
Interestingly, in a previously published study in oral carcinoma, the effect of 
CD36 inhibition was associated with inhibition of metastasis, but not with growth 
of primary oral cancers [150]. In contrast to these findings, our study suggests a 
critical role of CD36 in CRC proliferation and tumor growth in vivo with both 
chemical inhibition via SSO as well as shRNA-mediated knockdown of CD36 in 
xenografts using multiple established cell lines. 
  
Novel FASN inhibitors, TVBs, have demonstrated anticancer activity in 
multiple preclinical models [129], and TVB-2640 is currently in a number of clinical 
trials, including one at the University of Kentucky’s Markey Cancer Center 
(https://www.cancer.gov/about-cancer/treatment/clinical-trials/search/v?id=NCI-
2016-01710&r=1). Thus, it is crucial to identify and understand potential resistance 
mechanisms to FASN-targeted therapy. The current study demonstrates that 
inhibition of FASN leads to upregulation of CD36 expression and its translocation 
to the plasma membrane. One of the primary roles of CD36, when located within 
the cell membrane, is the transport of FAs [194, 238]. Therefore, this upregulation 
of membrane bound CD36 and, consequently, an increase in FA uptake, could be 
a potential mechanism of resistance to FASN inhibition. Importantly, our data 
demonstrate that the combined inhibition of CD36 and FASN has a synergistic 
effect on inhibition of cellular proliferation as well as survivin and cyclin D1, further 
suggests that targeting FA uptake may be a potential therapeutic approach to 
increase the efficacy of FASN inhibitors. 
We have previously reported that the level of FASN expression determines 
the sensitivity of tumors to TVB compounds [185]. Consistently throughout this 
study, we observed that higher expression of CD36 in HT29 LuM3 cells [254], as 
compared to parental HT29 cells, makes these cells more sensitive to CD36 
inhibition via CD36 shRNA and increases xenograft tumor growth inhibition 
compared to HT29 xenografts. Furthermore, the mutational and metabolic profiles 
of tumors determine tumor cell response to multiple therapies including metabolic 
inhibitors [265, 266]. Different genetic profiles and metabolic features can explain 
the varying levels of response to FASN and CD36 inhibition. Pt 93 and Pt130 cells 
have KRAS and V600E BRAF mutations. Pt 130 also carries an FGFR mutation 
[185]. The HCT116 cell line is a KRAS mutant, but BRAF wild type, compared to 
HT29 which has a V600E BRAF mutation but KRAS wild type [267]. Furthermore, 
TVB-3664 seems to have more efficacy in activating PARP cleavage compared to 
SSO, suggesting that the inhibition of lipid synthesis leads to activation of 
apoptosis through distinct pathways other than those related to the inhibition of 
exogenous FA uptake. Our ongoing studies in the laboratory are focused on 
identifying the mutational and metabolic features of tumors that would determine 






 Multiple studies suggest that FA metabolism in adipose tissue is a major 
contributor to the etiology of obesity and diabetes [268]. Obesity is associated with 
chronic elevation of free FAs (FFA) within the blood serum, which promote insulin 
resistance and contribute to the development of systemic hyperglycemia [269]. 
Interestingly, FASN expression is directly linked to obesity and type 2 diabetes 
[270] and CD36 protein expression is upregulated in both obese patients and type 
2 diabetics [271]. Therefore, the findings from this study support the idea that 
targeting both FASN and CD36 in combination may have therapeutic potential not 
only in cancer but also in metabolic disorders such as obesity and diabetes.  
 
This report is the first to describe the functional importance of CD36 and its 
indolent role in FA metabolism in the setting of CRC. It is also the first to describe 
the interconnection between FASN and CD36 and provides a strong rationale for 
further investigation into the interconnection of de novo lipogenesis and FA uptake 
that could potentially lead to the development of new therapeutic strategies for 
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Figure 2.1 CD36 is overexpressed in human CRC.  
(A-B) Immunoreactivity score of CD36 expression was analyzed in matched 
normal colon mucosa and tumor tissues from patients diagnosed with Stage I-IV 
CRC (TMA: n=56, *p<0.001 vs. normal tissue). (C) CD36 staining in matched 
normal colon mucosa, primary CRC and CRC metastasis to liver and lung 
(representative images are shown; liver [n=12] and lung metastasis [n=5]) (D). 
Correlations between FASN and CD36 was determined based on RNASeq data 
of CRC patient samples (n=22 of normal tissues and n=215 of tumors) from The 
Cancer Genome Atlas. (E) Expression of FASN and CD36 in human normal colon 
mucosa and tumor tissues. N-normal mucosa, T-primary tumor, L- normal liver 









Figure 2.2 Expression of CD36 is selectively regulated by the level of de 
novo FA synthesis in CRC. 
(A) shRNA-mediated knockdown of FASN leads to upregulation of CD36 mRNA 
expression in HCT116 cells. (B) TVB-3664 treatment of CRC tissue slices (18h) 
selectively upregulates CD36 mRNA expression. (C) TVB-3664 treatment of Pt 93 
and Pt 130 primary CRC cells increases CD36 mRNA and protein expression. (D) 
shRNA mediated knockdown of FASN increases CD36 protein expression in 
HCT116 and HT29 cells. (E) Relative mRNA expression of FASN and CD36 in 
intestinal tumors collected from APC/Cre and FASN+/-/APC/Cre mice. (F) FASN 
and CD36 protein expression in intestinal mucosa collected from Apc/Cre and 
Apc/Cre mice with hetero- and homozygous deletion of FASN. (G-H) Inhibition of 
FASN increases membrane-associated expression of CD36. (G) Confocal images 
of FASN and CD36 in control and 0.2μM TVB-3664 treated (6 days) Pt 93 primary 
CRC cells. (H) Flow cytometry analysis of Pt 93 and Pt 130 primary CRC cells 
treated with 0.2uM TVB-3664 (6 days) in normal and serum free media conditions. 
Mean fluorescence for CD36 is shown for representative data from 3 different 
experiments (**p<0.01, *p<0.05). (I) FA uptake in HCT116, NTC and FASN 
shRNA. Cells wre pre-treated with anti-CD36 antibody or vehicle for 24hrs and 






Figure 2.3 Inhibition of CD36 is associated with decreased cellular 
proliferation. 
(A) Primary Pt 93 and Pt 130 CRC cells treated with 100 μM SSO for 6 days. 
Cellular proliferation assays were performed via cell count. Representative data 
from 3 experiments is shown (*p<0.05). (B) Confocal images of FASN and CD36 
in Pt 93 cells in normal and serum free media (6 days). (C) Expression of proteins 
associated with apoptosis and survival in HCT116 transfected with CD36 shRNAs 
and analyzed via western blot. D) Cellular proliferation assay with HCT116, NTC 
and CD36 shRNA (*p<0.05). (E) qRT-PCR confirmation of CD36 knockdown using 





















Figure 2.4 SSO treatment and CD36 knockdown inhibit tumor growth in 
vivo. 
(A) Tumor volume, tumor weight and mouse weight of control and SSO treated 
(20mg/kg) mice are shown. SSO was dissolved in 10% PEG and administered in 
200 µl dosages via oral gavage daily. 1.0 x 106 cells were injected into NU/NU 
mice. Treatment was initiated when tumors reached approximately 100mm3 (day 
0). (B) RT-PCR analysis of HCT116 tumors showing the effect of SSO treatment 
on CD36, FASN and survivin mRNA expression. (C) Tumor volume of HCT116 
NTC and CD36 shRNA #2 and #4 xenografts is shown. 1.0 x 106 cells were 
injected into NU/NU mice and tumor growth was measured every 3 days. (D) H&E 
and Ki67 staining of HCT116 NTC and CD36 shRNA tumors. (E) Tumor volume 
and tumor weight of HT29 LuM3 NTC and CD36 shRNA #4 xenografts are shown. 
(F) mRNA expression of survivin in HT29 LuM3 xenografts (analysis of tumors 
















Figure 2.5 High expression of CD36 is associated with an increase in pAkt 
and survivin in CRC. 
(A) Diagram of Pt 2402 propagation after flow cytometry sorting for CD36high and 
CD36low cells. (B) Numbers of CD36high and CD36low Pt 2402 cells for 1st and 2nd 
flow cytometry sorts. (C) Protein expression levels of FASN, CD36 and survivin in 
CD36high and CD36low Pt 2402 primary cells from 1st flow cytometry sort. (D) IHC 
staining for Ki67 in Pt 2402 CD36high and CD36low tumors. (E) Protein expression 
levels of FASN, CD36, pAkt, cleaved PARP and survivin in HCT116 CRC cells, 

























Figure 2.6 Inhibition of CD36 and FASN have a synergetic effect in reducing 
cell proliferation. 
(A) Pt 93, Pt 130 and HCT116 cells were treated with SSO and TVB-3664 alone 
or in combination for 6 days and cell number was counted. Representative data 
from 3 experiments is shown (*p<0.05). (B) Western blot analysis of cells treated 



























Supplementary Figure S2.1 
(A) FASN mRNA expression is increased (*p < 0.0001) and (B) CD36 mRNA 
expression is decreased (*p < 0.0001) in CRC patient samples in the TCGA 
dataset (n=22 of normal tissues and n=215 of tumors). (C) Expression of FASN 




Supplementary Figure S2.2 
Expression of CD36 is regulated by the level of de novo fatty acid synthesis in 
CRC. (A) Protein expression of CD36 and FASN in FASN shRNA HCT116 and 
HT29 cells in both normal and hypoxic conditions. (B) mRNA expression of CD36 








Supplementary Figure S2.3 
CD36 upregulates survivin and inhibits apoptotic markers. (A) Effect of CD36 
overexpression on apoptotic markers was assessed in HCT116 cells, control and 
tdTomato-CD36, using Apoptosis Antibody Array. (B) Primary Pt 130 and Pt 93 
CRC cells were treated with 100μM SSO for 5 days in normal medium and 
expression of cleaved PARP, cleaved caspase-3, and survivin was analyzed. (C) 
3 x 104 HT29, NTC and CD36 shRNA #4, cells were plated in agarose and allowed 





Supplementary Figure S2.4  
(A) Expression of CD36 in CRC cell lines. (B) Tumor volume (mm3) of HCT116, 
NTC and CD36 shRNA#2 and #4 xenografts shown in Figure 4C. (C) Tumor 
growth for HT29 NTC and CD36 shRNA #2 and #4 xenografts. 2.0 x 106 cells were 
injected into NU/NU mice and tumor growth was measured every 3 days. (D) 
Tumor weight for HT29 NTC and CD36 shRNA #2 and #4 xenografts. (E) mRNA 




CHAPTER 3. CD36, A FATTY ACID TRANSLOCASE, PROMOTES 
METASTASIS VIA UPREGULATION OF MMP28 AND AN INCREASE IN          




Purpose: Altered FA metabolism, a hallmark of cancer, continues to be an 
attractive target for therapeutic intervention in cancer. Fatty Acid Translocase 
(CD36) has an important role in FA metabolism as a FA transporter. We have 
previously shown the importance of CD36 in the promotion of colorectal cancer 
(CRC) cell proliferation and tumorigenesis as well as its role in the compensation 
of de novo FA synthesis inhibition. CD36 has also been shown to play important 
roles in migration, invasion and metastasis in gastric, ovarian and oral carcinomas. 
Matrix metallopeptidase 28 (MMP28) is a member of the metallopeptidase family 
of proteins which is involved in the degradation of the extracellular matrix in various 
tissues. MMP28 is relatively novel and poorly investigated in cancer, however it 
has been shown to be involved in epithelial to mesenchymal transition (EMT) in 
lung and gastric carcinomas. We have previously shown that cell lines with a 
higher metastatic potential express higher level of CD36, however, the role of 
CD36 in CRC metastasis and its potential regulation of EMT has not been 
previously studied. The purpose of our study is (i) to determine the functional effect 
of CD36 on CRC metastasis and (ii) to delineate the mechanistic pathways in 
which CD36 may regulate CRC metastasis. 
 
METHODS: We utilized HCT116 and HT29 CRC cell lines as well as the 
HT29 LuM3-GFP-Luc cell line, which has been established from the HT29 cell line 
and has an increased propensity to metastasize to the mouse lung. An increase in 
metastatic capacity of HT29 LuM3 is associated with an increase in the expression 
of CD36 and MMP28. We utilize parental HT29-GFP-Luc and HT29 LuM3-GFP-
Luc to overexpress and knockdown CD36, respectively. We also use CD36 
neutralizing antibody to block activity of CD36 in HCT116 and HT29 LuM3 cells. 
To measure colonization, migration, and invasion we used soft agar colony 
formation and trans-well invasion assays. In vivo we utilized the tail-vein injection 
model and the orthotopic cecum injection model. We analyzed samples with qRT-
PCR, western blot, confocal microscopy, and immunohistochemistry. 
   
RESULTS: We found that knockdown of CD36 reduces CRC cell invasion 
and colony formation in HCT116 and HT29 LuM3 in vitro. CRC cell invasion and 
colony formation were increased with the overexpression of CD36 in HCT116 cells. 
Overexpression of CD36 in CRC cell lines increases mRNA and protein expression 
of survival and invasion markers including phospho-Akt, as well as MMP28. 
Knockdown of CD36 in HT29 LuM3-GFP-Luc cells significantly reduced lung 
metastasis in vivo and IHC staining of CD36 knockdown mouse lung tumors show 
a decrease in CD36 and MMP28 expression. Additionally, CD36 overexpression 
increased tumor growth and metastasis in cecum injected mice. siRNA mediated 




products of e-cadherin cleavage CTF1 and 2. shRNA knockdown of CD36 
decreases expression of MMP28 and significantly increases expression of e-
cadherin. Lastly, tissues analyzed from tail-vein injected mice, isogenic PDX 
tumors with high expression of CD36, and human CRC primary and liver 
metastasis tissues, show that with an increase in CD36 and MMP28 expression, 
there is a stark decrease in e-cadherin expression. 
 
CONCLUSION: CRC cells, which have a higher propensity to initiate 
metastasis in vivo, express higher levels of CD36 and MMP28. We show that this 
upregulation of CD36 and consequently MMP28 represents a unique advantage 
for CRC cells to initiate tumor colonies, migrate and invade both in vitro and in vivo. 
Furthermore, our study highlights the regulation of e-cadherin via cleavage by 
MMP28 in established CRC cell lines, PDXs, and human CRC tissues, suggesting 




 Colorectal cancer (CRC) is the leading cause of non-smoking related 
cancer deaths and the second leading cause of all cancer related deaths in both 
the United States and the world [1, 2]. Patients diagnosed with late-stage CRC, 
Stage III-IV, which exhibit local invasion and distant metastatic disease, have 
nearly a 10 fold decrease in 5 year survival rate when compared to earlier stage, 
localized disease [18, 19]. Despite advances in the treatment of primary CRC, 
there remains a lack of effective therapeutic strategies for late-stage CRC.  
Altered FA metabolism is recognized as a hallmark of cancer and multiple studies 
suggested targeting this pathway as a potential therapeutic strategy for cancer 
including CRC [128-130]. Fatty acid translocase (CD36) plays a significant role in 
dietary FA regulation as an exogenous FA transporter [194, 238]. CD36 can be 
membrane bound, where it can bind low density lipoproteins and extracellular long-
chain and ultra-long chain free FAs [194, 272]. CD36 has been implicated in the 
promotion of primary tumor proliferation and disease progression in multiple 
malignancies including ovarian, glioblastoma, and breast cancers [149, 151, 241, 
273]. Recently, our lab has shown the important role CD36 plays in the proliferation 
and progression of primary CRC and identified upregulation of CD36 as a potential 
mechanism of resistance to FASN-targeted therapy [274]. 
  
While compelling evidence exists to support CD36’s role in the promotion 
of primary tumor growth and progression in several diseases, there is some 
evidence to also suggest that CD36 may play a critical role in cancer metastasis. 
CD36 was shown to promote oral carcinoma migration and invasion in vitro and 
metastasis in vivo [150]. In fact, an enhanced presence of tumor cells expressing 
high levels of CD36 and an increase in metastatic potential is associated with a 
poor prognosis and clinical outcome in both glioblastoma and oral carcinoma [149, 
150]. Additionally, CD36 enhances in vitro migration and invasion in gastric cancer 
cells as well as local invasion and metastasis in vivo in ovarian cancer xenografts 




metastasis as well as epithelial to mesenchymal transition (EMT) in cervical cancer 
[275, 276]. However, the potential role of CD36 in CRC metastasis has not been 
previously studied. 
 
EMT is the fundamental process to which an epithelial cell acquires a more 
mesenchymal phenotype [277, 278]. Aside from the EMT process being utilized 
during normal tissue development, wound healing, and tissue repair, EMT has also 
been identified as one of the crucial steps involved in cancer metastasis [279-281]. 
Various molecular pathways and markers are implicated in the regulation of EMT 
in CRC, including Snail/Slug, Wnt/B-catenin and particularly the down-regulation 
of e-cadherin, a critical component of cell-cell adhesion junctions [282].  
 
Loss of e-cadherin is a key characteristic of EMT initiation in various 
cancers including CRC [223, 283]. E-cadherin expression has previously been 
shown to be a good prognostic marker for patients with CRC [284]. Furthermore, 
loss of e-cadherin increases CRC cell invasion and is correlated with poor survival 
rates of CRC patients [285, 286]. Moreover, lower expression of e-cadherin in CRC 
patient tumors is associated with tumor differentiation, invasion depth, tumor stage 
and lymph node metastasis [287]. Although e-cadherin has several know 
transcriptional regulators including both Snail and Slug, it is suggested that e-
cadherin is strictly regulated post-transcriptionally in CRC, either through 
stabilization or cleavage [288, 289]. However, even with multiple studies showing 
compelling evidence that lack of e-cadherin expression promotes disease 
progression, exact mechanisms of e-cadherin loss in CRC are still poorly 
understood. 
 
The matrix metallopeptidase (MMP) family of proteins have been shown to 
play an important role in the degradation of several extracellular matrix (ECM) 
components [290, 291]. MMP28, one of the newest members of this family of 
proteins to be identified, has been shown to be associated with EMT in lung 
carcinoma [292]. Furthermore, MMP28 is associated with a poor prognosis and 
lower survival rates in gastric cancer and increased expression of MMP28 is 
associated with an increase in invasion and colony formation of gastric cancer cells 
in vitro and in vivo [293, 294]. Lastly, MMP28 induced EMT in lung carcinoma is 
associated with a significant loss of e-cadherin expression [295, 296].  
  
Since previous studies have implicated CD36’s involvement in the 
metastatic process and regulation of EMT in multiple cancers, the goal of this study 
was to evaluate the contribution of CD36 to CRC metastasis. 
 
We found that CD36 promotes invasion and colony formation of CRC cells 
in vitro. We also found that established HT29LuM3 cell line which have a higher 
propensity to initiate lung colonies in mice via the tail-vein injection model as 
compared to parental HT29 cells, express significantly higher levels of CD36 and 
uptake more FFAs in a CD36 dependent manner [254]. Additionally, we also found 




cell lines and isogenic patient derived xenografts. Our results also show that 
knockdown of MMP28 reduces CRC cell invasion in vitro. Furthermore, CD36 
knockdown significantly reduces lung colony formation in vivo. Lastly, we found 
that CD36 and MMP28 expression are inversely associated with e-cadherin 
expression in CRC cells. We show that high level of MMP28 expression is 
associated with an increase in the cleavage of e-cadherin and an increase in the 
cleavage products of e-cadherin; C-terminus fragment 1 and 2 (CTF1 and CTF2). 
CTF1 contains both the transmembrane and cytoplasmic domains of e-cadherin 
and is produced after cleavage [297]. CTF1 can then be processed and cleaved 
between the cytoplasmic and trans-membrane domains by the Presenilin-1, 
resulting in the release of CTF2 [297, 298]. 
 
Together these findings implicate that CD36 promotes metastasis via 
upregulation of MMP28 and e-cadherin cleavage and, thus, may be a viable 




3.3.1 CD36 Promotes Invasion and Colony Formation in HCT116 Cells 
 
 We have previously shown that CD36 promotes CRC proliferation 
and survival in in vitro and in vivo [274]. There is also compelling evidence that 
CD36 contributes to invasion and migration in various cancers including 
glioblastoma, oral carcinoma, gastric, and ovarian cancer [149-151, 241], but 
CD36 has not yet been investigated in CRC metastasis. Here, we found that 
shRNA-mediated knockdown of CD36 in HCT116 cell line leads to a significant 
reduction in invasion as compared to non-targeted control HCT116 cells (Figure 
3.1 A, D). Furthermore, when CD36 is overexpressed in HCT116 cells, we 
observed a significant increase in cell invasion and colony formation (Figure 3.1 
B-D).  Together, these data suggest that CD36 is substantially involved in the 
invasion and colony formation of established CRC cells. 
 
3.3.2 CD36 Expression is Associated with a More Metastatic Phenotype in 
Isogenic CRC Cell Lines 
 
 To further investigate any potential role CD36 may play in metastasis 
of CRC, we utilized the HT29 LuM3-GFP-Luciferase trained cell line, a cell line 
which was serially injected via tail vein in mice and has a significantly higher 
propensity to initiate lung colonies than the parental HT29 cell line [254]. We have 
previously shown that CD36 is significantly upregulated in the HT29 LuM3 cell line 
as compared to parental HT29 [274].  Figures 3.2 A-B demonstrate higher CD36 
expression HT29 LuM3 cell line compared to parental HT29 using western blot and 
confocal microscopy, respectively. Additionally, confocal microscopy of FA uptake 
using BODIPY ™ 558/568 C12 demonstrates that HT29 LuM3 cells uptake more 
free FAs than parental HT29 cells in a CD36-dependent manner (Figure 3.2 C).  




increases colony formation and colony diameter (Figure 3.2 D). Together these 
data suggest that CD36 is upregulated in the HT29 LuM3 cell line and associated 
with acquired more invasive and metastatic behavior of this cell line reported 
previously [254]. Additionally, the data also suggests that increased expression of 
CD36 is also associated with an increase in uptake of extracellular FAs.   
 
3.3.3 CD36 Promotes Lung Colonization and Orthotopic Metastasis in vivo 
 
To more-thoroughly investigate the role CD36 may play in CRC metastasis, 
we tested the effect of CD36 on colonization and metastasis in vivo. Utilizing the 
HT29 LuM3 model, we established a HT29 LuM3-GFP-Luciferase non-targeted 
control (NTC) and CD36 knockdown (shCD36) cell lines and injected these cells 
via tail vein into NU/NU (n=5 each) mice and monitored for lung colony formation. 
Mice injected with the HT29 LuM3 shCD36 cell line exhibited significantly lower 
luciferase reporter bioluminescence signal as compared to mice injected with 
HT29 LuM3 NTC cells (Figure 3.3 A). Furthermore, resected lungs from both NTC 
and shCD36 injected mice show that mice injected with HT29 shCD36 cells have 
substantially lower GFP signal and tumor burden than those injected with HT29 
NTC (Figure 3.3 B-C). The levels of CD36 mRNA expression in these cells are 
shown in Figure 3.3 D. 
  
 To better recapitulate the condition of local invasion and metastasis with 
CRC, we also used the orthotopic cecum injection mouse model. The cecum 
injection model is well established in vivo model which replicates human disease 
with a higher level of accuracy than other ectopic models [299]. To study CD36’s 
role in CRC metastasis in a more translational way, we injected 1 x 106 HCT116 
p-Lenti-Control or p-Lenti-CD36 overexpressing cells in 50µl of PBS into the cecum 
wall of NU/NU (n=5) mice. Our data shows that mice injected with p-Lenti-CD36 
overexpressing HCT116 cells exhibited an increase in the number of primary 
tumors formed compared to mice injected with p-Lenti-Control cells. More 
importantly, we identified GI metastasis in all mice injected with p-Lenti-CD36 
overexpressing cells; however, no metastases were found in mice injected with p-
Lenti-Control cells (Figure 3.3 E-G). The level of CD36 overexpression in HCT116 
cells is shown in Figure 3.3 H. 
 
Together, the results of animal experiments support our in vitro data and 
suggest that CD36 significantly contribute to CRC invasion and metastasis.  
 
3.3.4 CD36 is Associated with MMP28 Expression 
 
Gene enrichment analysis of parental HT29 p-Lenti-Control and p-Lenti-
CD36 overexpression cell lines show an enrichment of pathways involving focal 
adhesion, extracellular matrix protein interaction and gap junctions (Figure 3.4 A). 
Additionally, RNA-Seq analysis of both cell lines showed that CD36 expression is 





MMP28 is the newest member matrix metallopeptidase to be identified and 
is involved in ECM degradation [292]. MMP28 is associated with metastasis in lung 
and gastric cancer [295, 296], but has not yet been studied in CRC. To confirm 
RNA-Seq data, we performed qRT-PCR analysis of HT29 LuM0, p-Lenti-Control 
and p-Lenti-CD36 overexpression, and HT29 LuM3, NTC and CD36 shRNA, cells. 
As shown in Figure 3.4 C, overexpression of CD36 in HT29 cells leads to 
significant upregulation of MMP28 mRNA. In contrast, shRNA-mediated 
knockdown of CD36 in HT29 LuM3 cells leads to a decrease in MMP28 mRNA 
expression. Consistently, HCT116 cells with CD36 overexpression also exhibit 
higher levels of MMP28 mRNA expression and inversely, HCT116 CD36 shRNA 
cells show a significant decrease in MMP28 mRNA expression (Figure 3.4 D). 
Furthermore, HCT116 and HT29 LuM0 cell lines with CD36 overexpression also 
display higher protein expression of MMP28, and the pro-survival marker p-Akt 
(Figure 3.4 E) [300]. To further support the association between CD36 and 
MMP28, we show that HT29 LuM3 cells, which express higher levels of CD36, also 
express higher levels of MMP28 protein compared to the parental HT29 LuM0 cell 
line as shown by Western blot and confocal microscopy (Figure 3.4 F-G). 
  
Together these data show a strong association of CD36 with MMP28 at 
mRNA and protein levels, suggesting that CD36 may indeed regulate the 
expression of MMP28.        
 
3.3.5 MMP28 Promotes CRC Cell Invasion and Reduced Expression of E-
Cadherin in vitro 
 
 Previously published data suggests that MMP28 plays a critical role in the 
regulation of metastasis in lung and gastric cancers. Particularly, MMP28 has been 
shown to promote EMT in lung carcinoma and increased of expression of MMP28 
is associated with a loss of e-cadherin [295, 296]. Loss of e-cadherin is a well-
established marker for EMT initiation and poor clinical outcome in various cancers 
including CRC [283]. MMP28, however, has not been previously studied and it has 
not been mechanistically investigated in relation to e-cadherin in CRC.  
 
To further elucidate the role of MMP28 in CRC metastasis, we established 
a transient knockdown of MMP28 in HCT116 cells using MMP28 siRNA. HCT116 
siMMP28 cells display a significantly lower ability to invade across a Matrigel 
Trans-Well as compared to control cells transfected with scrambled siRNA (Figure 
3.5 A). Furthermore, a decrease in MMP28 mRNA expression due to transfection 
with MMP28 siRNA leads to a significant increase in mRNA expression of e-
cadherin when compared to cells transfected with scrambled siRNA control 
(Figure 3.5 B). Western blot analysis of the HT29-LuM3-GFP-Luciferase NTC and 
CD36 shRNA knockdown cells demonstrates a reduction in MMP28 expression 
and an increase in e-cadherin expression further supporting that MMP28 regulates 
expression of e-cadherin downstream of CD36 (Figure 3.5 C). The levels of e-
cadherin expression can be regulated transcriptionally or by e-cadherin cleavage 




e-cadherin, such as through the regulatory proteins Slug or Snail [288, 289], in 
response to altered expression of CD36 or MMP28. However, to our surprise, 
when we analyzed our HT29-LuM3-GFP-Luciferase NTC and CD36 shRNA 
knockdown cells along with control HCT116 cells and cells transfected with 
MMP28 siRNA by western blot analysis, we found that MMP28 is not only 
associated with a decrease in functional e-cadherin (135 kD), but also associated 
with an increase in the cleavage products of e-cadherin, CTF1 and CTF2 (Figure 
3.5 C-D). While knockdown of CD36 slightly reduced the levels of CTF1, 
knockdown of MMP28 is associated with almost complete abolishment of e-
cadherin cleavage (Figure 3.5 C-D) suggesting that MMP28 plays a crucial role in 
the regulation of e-cadherin, potentially via direct cleavage. These data suggest 
that CD36 increases the invasive and metastatic potential of CRC cells by 
regulating EMT via the induction of MMP28 and the cleavage of e-cadherin.   
 
3.3.6 Overexpression of CD36 is Associated with an Increase in MMP28 
Expression and a Reduction of E-cadherin in vivo and in Human CRC Specimens 
 
To support our data on CD36/MMP28 and e-cadherin axis in CRC 
metastasis, we analyzed expression of CD36, MMP28 and e-cadherin in lung 
tissues resected from mice injected with HT29 LuM3, NTC and CD36 shRNA, cells 
(Figure 3.3 A). IHC analysis demonstrates that reduction of CD36 and MMP28 
expression is associated with an increase in e-cadherin expression in tumor 
lesions with CD36 knockdown as compared to NTC tumor tissues (Figure 3.6 A). 
   
Our lab has previously shown that isogenic patient derived xenograft (PDX) 
tumors, which were established from isolating tumor cells expressing high levels 
of CD36 (CD36high), have a higher propensity to grow subcutaneous tumors in vivo 
[274]. To further confirm the relationship between CD36, MMP28 and e-cadherin, 
we analyzed tissues from Pt2402 CD36high and CD36low   PDXs. Western blot 
analysis and IHC staining confirms that low expression of CD36 is associated with 
low expression of MMP28 and an increase in the level of e-cadherin (Figure 3.6 
B-C).  
 
To translate our findings from in vitro and in vivo to human tissues, we 
analyzed expression of CD36, MMP28 and e-cadherin in matched normal mucosa, 
primary CRC and liver metastasis specimens. Our data shows that as we transition 
from normal tissue to primary tumor and then metastasis, we see an increase in 
the expression of both CD36 and MMP28 (Figure 3.6 D). Furthermore, we 
inversely see a decrease in the expression of e-cadherin as we move from normal 
tissues to primary and metastatic tumors (Figure 3.6 D). In agreeance with our in 
vitro data, these human tissues also show an increase in the cleavage product of 
e-cadherin, CTF2, as disease progresses, suggesting that MMP28, through CD36 
regulation, may directly cleave e-cadherin. Furthermore, when analyzing the 
expression CD36, MMP28, and e-cadherin in unmatched normal mucosa, primary 
and metastatic CRC tissues, we see a pattern of expression which is in agreeance 




intriguing relationship between CD36 and MMP28, and that of e-cadherin 




Previous investigations from our lab have revealed that CD36 plays an 
important role in the survival and proliferation of CRC cells and its specific 
upregulation may be a potential compensation mechanism when de novo FA 
synthesis is inhibited in CRC [274]. Aside from the pro-survival and tumorigenic 
properties of CD36, CD36 has been implied in the promotion of invasion and 
metastasis in multiple oncogenic diseases [149-151, 275, 301]. Despite this 
knowledge, the role of CD36 in the process of invasion and metastasis of CRC has 
not yet been investigated. 
 
In parallel with previous reports that suggest CRC promotes invasion and 
metastasis of ovarian and gastric cancer cells in vitro, we found that CD36 
promotes colony formation and trans-well invasion of CRC cells in vitro [151, 242]. 
We also found that CRC cells which exhibit a more metastatic phenotype express 
higher levels of CD36 and uptake more exogenous FAs in a CD36-dependent 
fashion.  
 
One of the premier studies investigating the role of CD36 in metastasis was 
that of Pascual et al. which described the pro-metastatic characteristic of CD36 in 
oral carcinoma. It was reported that a subpopulation of oral carcinoma cells which 
express high levels of CD36 were unique in their ability to initiate metastasis in 
vivo [150]. Additionally, they found that knockdown or inhibition of CD36 did not 
affect oral carcinoma primary xenograft tumor growth, but almost completely 
abolished local invasion [150]. In contrast to their findings, our previous study 
showed that CD36 does play an important role in primary CRC tumor growth, in 
particular when endogenously synthesized FAs are limited [274]. However, our 
current study is in agreeance with their findings on metastasis, suggesting that 
CD36 is also critical for CRC invasion and metastasis. Consequently, our findings 
here are also in parallel with several other studies which suggest that CD36 
promotes metastasis in vivo [149-151, 242].  
 
It is worth noting that due to CD36’s role in the survival and proliferation of 
CRC cells, it is possible that this may also be responsible for the effect of CD36 on 
CRC metastasis. Therefore, it is critically important to identify a potential 
mechanistic pathway which distinguishes the pro-survival characteristics of CD36 
from any pro-metastatic ones. Previously we described that CD36 is associated 
with increased levels of the pro-survival marker survivin in primary CRC [274]. We 
also showed that an increase in expression of CD36 is associated with an increase 
in phosphorylation of Akt [274].  The Akt pathway is implicated in regulation of both 
cancer cell survival and metastasis [300]. Previously published study has 
implicated that CD36 promotes metastatic disease in gastric cancer via the 




that overexpressing CD36 increases cell invasion and colony formation and is 
associated with increased levels of p-Akt in established CRC cell lines. However, 
an increase in phosphorylation of Akt alone is not sufficient to describe a metastatic 
advantage for CRC.  
 
As previously mentioned, the process of EMT is recognized as one of the 
crucial steps involved in cancer metastasis and a hallmark of cancer [229, 280, 
302]. The remodeling of the extracellular matrix is critical for cells to escape their 
primary environment and enter a system of circulation (lymph or blood) where they 
then travel to distant sites and colonize new metastatic tumors [302]. It has been 
previously shown that increased FA uptake via CD36 is associated with EMT 
progression in hepatocellular carcinoma cells [222]. Furthermore, CD36 has been 
shown to promote EMT in cervical cancer through interactions with TGF-beta 
pathway [220]. More specifically, treatment of cervical cancer cells with TGF-beta 
increased CD36 expression and exhibited a significant loss in the expression of e-
cadherin [220]. Loss of e-cadherin is critical marker for EMT and a well-established 
hallmark of cancer [302].  Interestingly, our studies show that overexpression of 
CD36 promotes loss of e-cadherin through a relatively novel member of the MMP 
family of proteins, MMP28.  
 
A few members of the MMP family of proteins have been linked to EMT in 
multiple diseases [303-305]. Particularly, MMP-3 and 7 have been shown to 
promote EMT in breast cancer cells in vitro through direct cleavage of e-cadherin 
[303, 305]. In most studies, those tumors expressing higher levels of various MMPs 
result in a poor prognosis for patient survival [304]. As previously mentioned, 
MMP28 is the newest member of this family of proteins to be identified and is 
associated with EMT in lung carcinoma [292]. Additionally, MMP28 is associated 
with invasion and colony formation in gastric cancer cells and increased MMP28 
expression is a poor prognostic factor for gastric cancer patients [293, 294]. Our 
studies show here, for the first time, that CD36 is associated with MMP28 
expression in CRC and that MMP28 expression is associated with increased CRC 
cell invasion and metastasis. We also show here that MMP28 expression is 
associated with a loss of the critical EMT marker e-cadherin. Along with this loss 
of e-cadherin, MMP28 expression is associated with increased levels of the 
cleaved C-terminal fragments of e-cadherin CTF1 and CTF2 [298]. It is worth 
noting that aside from simply being cleavage products of e-cadherin, the CTFs 
themselves can act as downstream signaling molecules, such as interacting with 
and preventing β-catenin degradation as wells as aiding in the translocation of β-
catenin to the nucleus, promoting transcription of various downstream genes [306]. 
Because of the prominent role that the Wnt/ β-catenin pathway plays in CRC, 
further investigation into the MMP28-e-cadherin-CTF association described here 
may yield greater information on the mechanisms of CRC progression and 
metastasis.  
 
Aside from showing just a direct relationship between MMP28 and e-




expression of CD36 significantly upregulates e-cadherin in CRC cell lines, isogenic 
PDXs and patient tissues. To our knowledge, this is the first known study to 
demonstrate the association of CD36 with MMP28 expression and the loss of e-
cadherin. Our study is also the first to suggest that MMP28 may be directly involved 
in the cleavage of e-cadherin in CRC. Therefore, the data presented here show 
that CD36 may play an important role in the regulation of metastasis in CRC 




Late stage CRC, categorized by advanced disease with distant metastasis, 
remains one of the deadliest cancers in the United States and the world [1]. New 
therapeutic strategies to identify and target tumor cells with higher metastatic 
potential is needed to improve the efficacy of treatment and increase overall patient 
survival. Together, this study highlights the potential of both CD36 and MMP28 as 
therapeutic targets for CRC. Further investigation into the exact mechanistic 
regulation of MMP28 by CD36 and MMP28’s interaction with e-cadherin is needed 
to potentially develop new more effective treatment strategies for patients with late-












Figure 3.1 CD36 promotes invasion and colony formation in CRC cell lines. 
(A) Matrigel trans-well invasion assay. Average count of invaded cells/field, 
absorbance at 560 nm of de-stained Matrigel trans-well invasion chambers and 
raw images of HCT116 NTC and CD36shRNA cell lines are shown. (B) Matrigel 
trans-well invasion assay. Average count of invaded cells/field, absorbance at 
560 nm of de-stained Matrigel trans-well invasion chambers and raw images of 
HCT116 p-Lenti-Control and p-Lenti-CD36 overexpression cell lines are shown. 
(C) Quantification and representative images of HCT116 p-Lenti-Control and p-
Lenti-CD36 overexpression soft agar colony formation assays. (D) q-RT-PCR 
demonstrating the levels of knockdown and overexpression CD36 in HCT116 


















Figure 3.2 CD36 expression is associated with more metastatic CRC cell 
lines. 
(A) Western blot analysis of HT29 LuM0 and LuM3 GFP-Luciferase cell lines. (B) 
Confocal microscopy images of HT29 LuM0 and LuM3 GFP-Luciferase cells for 
CD36 expression (red), nucleus (blue) and actin filaments (purple). (C) FA uptake 
assay confocal microscopy images of HT29 LuM0 and LuM3 GFP-Luciferase 
control or treated with anti-CD36 neutralizing antibody for 24h (lipid analogue – 
red, DAPI – blue). (D) Quantification and representative images of HT29 LuM0 p-






















            
Figure 3.3 CD36 promotes lung colonization and metastasis in vivo. 
(A) Representative images and quantification of luciferase assay bioluminescence 
imaging in tail-vein injected mice of HT29 LuM3 GFP-Luciferase cells, NTC (n=5) 
and CD36shRNA (n=5). (B) GFP imaging and (C) H&E staining of lung tissues of 
resected lungs of tail vein injected mice. (D) qRT-PCR quantification of CD36 in 
HT29 LuM3 GFP-Luciferase NTC and CD36sh RNA cell lines. (E) Images from 
HCT116 control and CD36 overexpression cecum injected mice showing 
increased tumor burden and colon metastasis in the CD36 overexpression mice. 
(F) H&E staining of the resected primary and metastatic tissues from mice injected 
with control and CD36 overexpression HCT116 cells (M–metastasis). (G) 
Quantitative analysis of primary cecum tumors and GI metastasis. (H) qRT-PCR 
quantification of CD36 in HCT116 p-Lenti-Control and CD36-Overexpression cell 





Figure 3.4 CD36 regulates expression of MMP28. 
(A) Representative gene set enrichment analysis (GSEA) plots generated from 
RNA-seq expression data of HT29 p-Lenti Control and HT29 p-Lenti CD36 
overexpression cell lines. The top 10 enriched pathway sets are provided 
in Supplemental Figure 3.2. Bar codes indicate the location of gene set members 
in the ranked list of all genes. ES, enrichment score; NES, normalized enrichment 
score; NOM, nominal p-value; FDR, false discovery adjusted p-value. (B) Volcano 
plot of HT29 p-Lenti Control and HT29 p-Lenti CD36 overexpression cell lines 
showing increased levels of CD36 mRNA associated with an increase in MMP28 
mRNA expression. (C) qRT-PCR analysis of CD36 and MMP28 mRNA in HT29, p-
Lenti Control and p-Lenti CD36 overexpression cell lines, and in HT29 LuM3 GFP-
Luciferase NTC and shCD36 cell lines. (D) qRT-PCR analysis of CD36 and 
MMP28 mRNA in HCT116, p-Lenti Control and p-Lenti CD36 overexpression, and 
HCT116, NTC and CD36 shRNA cell lines. (E) Western blot analysis of HCT116 
and HT29 LuM0 p-Lenti Control and p-Lenti CD36 overexpression cell lines for 
CD36, MMP28, p-Akt and total Akt. (F) Western blot of analysis of CD36 and 
MMP28 in HT29 LuM0 and HT29 LuM3 GFP-Luciferase cell lines. (G) Confocal 
microscopy of HT29 LuM0 and HT29 LuM3 GFP-Luciferase cell lines for actin, 







Figure 3.5 MMP28 reduces CRC cell invasion and decreases expression of 
functional e-cadherin in vitro. 
(A) Normalized average count of invaded cells/field, absorbance at 560 nm of de-
stained Matrigel trans-well invasion chambers and raw images of Matrigel trans-
well invasion chambers of HCT116, siControl and siMMP28 cell lines. (B) qRT-
PCR analysis of control and MMP28 siRNA transfected HCT116 cell lines for 
MMP28 and e-cadherin. (C) Western blot analysis of HT29 LuM3 NTC and 
shCD36 cell lines for CD36, MMP28 and e-cadherin. (D) Western blot for MMP28 
and e-cadherin expression. Western blots including e-cadherin cleavage products 
CTF1 and CTF2 are shown on separate blots (long and short exposure). (*p <.05, 








Figure 3.6 Overexpression of CD36 is associated with an increase in 
MMP28 expression and reduction in the level of e-cadherin in vivo and 
human CRC specimens. 
(A) IHC analysis of tissues from tail vein injection of HT29 LuM3 GFP-Luciferase 
NTC and shCD36 cell lines shown in Figure 3A. (B) Western blot analysis and (C) 
IHC analysis of tissues from Pt2402 PDX, CD36 low and CD36 high, isogenic 
tumors for CD36, MM28, and e-cadherin. (D) Western blot analysis of matched 
normal (N), primary tumor (PT) and liver metastasis (LM) tissues for CD36, 
MMP28, e-cadherin, and CTF2. (E) Western blot analysis of CD36, MMP28, and 






CHAPTER 4. FATTY ACID SYNTHASE PROMOTES TUMOR GROWTH VIA 
UPREGULATION OF HEXOSAMINE METABOLISM AND O-LINKED 




PURPOSE: The Adenomatous polyposis coli (APC) gene is an important 
regulatory gene involved in Wnt/β-catenin signaling. Mutations in the APC gene 
are associated with CRC tumorigenesis and progression. Animal models have 
been developed to study APC-driven tumorigenesis in vivo. Our lab has previously 
demonstrated the role of FASN in CRC proliferation and tumorigenesis. However, 
FASN has not yet been investigated in regard to APC-driven tumorigenesis. 
Therefore, the purpose of this study was to: (i) determine the effect of FASN 
deletion on adenoma formation and mice survival in the APC/Villin-Cre mouse 
model and (ii) deliniate potential signaling and metabolic pathways effected by 
altered FASN expression which may promote tumorigenesis in the APC/Villin-Cre 
mouse model. 
 
METHODS: We have developed mouse colonies bred from the APC/Villin-
Cre mouse model in combination with mice containing floxP FASN, resulting in 
FASN/Apc/Villin-Cre, FASN+/∆/Apc/Villin-Cre, and FASN∆/∆/Apc/Villin-Cre strains. 
Mice from FASN/Apc/Villin-Cre  and FASN+/∆/Apc/Villin-Cre strains, both male and 
female, were monitored for survival duration. Intestinal tissues from each strain 
were also analyzed for FASN expression via IHC and qRT-PCR and adenomas 
were counted on the sections of small intestine. RNA transcriptomes from 
adenomas collected from all three mouse strains were analyzed via RNA-seq 
analysis. Utilizing the list of identified differentially expressed genes (DEGs), the 
Gene enrichment analysis was performed. Metabolomic analysis of adenomas 
collected from FASN/Apc/Villin-Cre, FASN+/∆/Apc/Villin-Cre, and 
FASN∆/∆/Apc/Villin-Cre mice was performed using gas chromatography-mass 
spectrometry. The protein expression of metabolic enzymes in these mice was 
analyzed using the Reverse Phase Protein Array (RPPA). The primary cell lines, 
Pt 93 and P t130, were treated with GFPT1 inhibitor azaserine and OGT inhibitor 
OSMI1, and cell proliferation and colony formation assays performed. The 
established CRC cell line HCT116 was used to knockdown GFPT1 and OGT and 
utilized for subcutaneous xenografts in vivo.     
 
RESULTS: The high level of FASN expression is seen intestinal adenomas 
developed in Apc/Villin-Cre mice.  Heterozygous deletion of FASN leads to a 
significant increase in survival of both male and female mice. Consistently, 
significantly fewer adenomas formed in Apc/Cre mice with heterozygous deletion 
of FASN as compared to APC/Villin-Cre control mice. RNA-seq and gene 
enrichment analysis of tissues from FASN/Apc/Villin-Cre, FASN+/∆/Apc/Villin-Cre, 
and FASN∆/∆/Apc/Villin-Cre mice show a drastic change in global gene expression 
including alterations in pathways involved in cell proliferation, energy metabolism 




reveals significant decrease in abundance of multiple metabolites involved in the 
TCA cycle, glycolysis, and hexosamine biosynthesis. Importantly, the RPPA data 
demonstrate the deletion of FASN in mouse is associated with a significant 
decrease in expression of glutamine-fructose-6-phosphate aminotransferase 
(GFPT1) and O-Linked N-Acetylglucosamine Transferase (OGT), enzymes within 
the hexosamine biosynthesis pathway. More specifically, knockout of FASN 
reduces the mRNA and protein expression of both GFPT1 and OGT. Furthermore, 
inhibition of GFPT1 and OGT reduces primary CRC cell proliferation and colony 
formation in vitro. Lastly, knockdown of GFPT1 and OGT in HCT116 cells reduces 
tumor growth in vivo. 
 
CONCLUSIONS: Our data here shows that FASN promotes tumorigenesis 
in APC/Cre mouse model. Additionally, FASN also regulates multiple metabolic 
processes in these mouse strains, including that of hexosamine biosynthesis. 
Furthermore, we found that an increase in GFPT1 and OGT expression promotes 
CRC cell proliferation, colony formation and tumor growth. Together, this data 
further supports the fact that FASN is a desirable therapeutic target for CRC. 
Interestingly, our data here suggests that targeting the regulation of metabolic 
processes other than FA metabolism, such as hexosamine biosynthesis, by FASN, 
could potentially lead to the development of more efficacious treatment strategies 
in CRC. Lastly, our study emphasizes that further investigation into hexosamine 
biosynthesis and its regulation is needed to fully delineate the role this pathway 




Colorectal cancer (CRC) is currently the third most diagnosed cancer and 
the second most common cause of cancer related deaths in the world [1, 307]. 
CRC is primarily sporadic, resulting from a variety of environmental factors such 
as smoking and obesity, but can also be linked to genetic inheritance [308]. The 
Adenomatous polyposis coli (APC) gene is an important regulatory gene which 
binds to and sequesters β-catenin in the cytoplasm of the cell, preventing β-catenin 
translocation to the nucleus where it would then promote translocation of various 
pro-survival and proliferation genes [309]. Mutations in APC have been shown to 
be necessary for initiation of familial adenomatous polyposis (FAP) and mutated 
APC is suggested in the role of a driver mutation for CRC [309, 310].  
 
Several in vivo models have been developed in an attempt to more 
accurately investigate CRC initiation, progression, and metastasis. Some such 
models include mutations in and/or alteration in the expression of the APC gene 
[310]. A prominent mouse model focusing on APC is the APC multiple intestinal 
neoplasia (ApcMin/+) mouse model, in which the APC gene has a truncation 
mutation in codon 850. Mice with heterozygous min mutation in APC develop 
multiple small intestinal polyps which can progress to adenocarcinoma [311]. This 
model is an excellent experimental representation of APC driven FAP and sporadic 





Another prominent in vivo model targeting APC is the APC/Villin-Cre mouse 
model, in which the APC gene is flanked by loxP sequences and Cre recombinase 
is expressed within the crypt epithelial cells of the small and large intestine using 
the intestinal specific promoter sequence of Villin [313]. This results in intestinal 
specific deletion of APC, which thus leads to a phenotype comparable to that of 
the ApcMin mouse model [311, 313]. With this model, it is possible to study APC- 
driven tumorigenesis in vivo, and potentially identify other pathways which 
contribute to this phenomenon.  
 
Altered metabolism is commonly exhibited in CRC and is a hallmark of 
cancer and a potential target for therapeutic intervention [128-130, 314, 315]. Fatty 
acid synthase (FASN), a critically important enzyme of de novo lipogenesis, has 
previously been shown to be upregulated in CRC and involved in tumor 
progression and metastasis.[153, 231]  Previous studies from our lab show 
significant reduction of tumor growth in patient derived xenografts (PDXs) and 
primary cell proliferation in vitro when treated with TVB, a novel inhibitor of FASN 
developed by Sagimet Biosciences and currently in phase I/II clinical trials [185, 
191-193]. However, the role FASN may play in CRC tumor initiation and 
development has not yet been studied. 
 
Hexosamine metabolism involves the process known as glycosylation, in 
which a glycan is attached to a protein or other functional molecular target and is 
an important metabolic pathway involved in the development and regulation of 
various tissues and cellular processes [316]. This complex metabolic pathway is a 
branch of glycolysis and involves several enzymes. These include the entry and 
rate limiting enzyme glutamine-fructose-6-phosphate aminotransferase (GFPT1) 
as well as O-Linked N-Acetylglucosamine Transferase (OGT), which attaches the 
glycan (β-D-N-acetlyglucosamine (GlcNAc), to a hydroxyl group of serine or 
threonine moieties of molecular targets (O-GlcNAc)  [316-318]. The resulting 
proteins now containing an O-GlcNAc moiety are then used in a variety of cellular 
functions including cell signaling and metabolic flux. [317, 319, 320]. Altered levels 
of O-GLcNAc have been shown to correlate with cancer progression and altered 
glycosylation is also a hallmark of cancer [321, 322]. Furthermore, aberrant protein 
glycosylation is a pathological alteration that is frequently associated with onset 
and progression of CRC, cancer cells immunogenicity and drug resistance [323-
325]. It is suggested that O-GlcNAc may be directly modulated by several 
processes including FA metabolism [326]. However, any role of de novo lipid 
synthesis via FASN in the regulation of cellular glycosylation and their combined 
role in CRC has not been previously studied. 
 
We have bred an APC/Villin-CRE mouse along with mice containing a loxP-
flanked FASN gene expressed with the Villin promoter (FASN/Villin-Cre) resulting 
in a colony of mice in which both APC can be genetically deleted along with 
heterozygous or homozygous deletion of FASN (FASN+/∆ /Apc/Villin-Cre and 




FASN in combination with APC deletion live significantly longer than those with 
APC deletion alone. Furthermore, we show that both heterozygous and 
homozygous deletion of FASN in APC/Villin-Cre mice result in significantly lower 
numbers of adenomas in the intestine compared to APC/Cre control. Consistantly, 
we demonstrate that deletion of FASN downregulates several pathways including 
those involved in cell proliferation, energy metabolism, and CRC initiation and 
progression. More specifically, metabolic analysis of mouse tissues with FASN 
heterozygous and homozygous deletion reveals a significant alteration of multiple 
metabolites involved in glycolysis and the citric acid cycle (TCA). We further show 
that FASN regulates important enzymes in hexosamine biosynthesis, specifically 
GFPT1 and OGT. Deletion of FASN in mouse tissues significantly downregulates 
both OGT and GFPT1 as well as the product of glycosylation, O-GlcNAc. Lastly, 
we demonstrate that inhibition of glycosylation through the targeting of OGT and 
GFPT1 inhibits CRC cell proliferation, colony formation, and xenograft tumor 
growth in vivo.  
 
Together, the data presented here shows that FASN plays a significant role 
in the initiation of adenomas in the APC/Villin-Cre mouse model. Additionally, 
these results suggest that FASN may regulate hexosamine biosynthesis, which is 
an important metabolic pathway in the proliferation and progression of CRC.  
These results emphasize the need for further investigation into the mechanistic 
regulation of hexosamine biosynthesis by FASN. Furthermore, these results may 
provide further insight into the development of new, more-effective therapeutics 




4.3.1 Heterozygous Deletion of FASN Increases Survival and Decreases 
Adenoma Burden in vivo 
 
 To analyze the potential role of FASN on CRC initiation and adenoma 
formation, we utilize the APC/Villin-Cre and FASN/Apc/Villin-Cre mouse models. 
IHC analysis of tissues from APC/Villin-Cre mice show that FASN is highly 
expressed in tumor tissues (Figure 4.1 A). C57BL/6J mice with LoxP-flanked 
FASN alleles were bred with APC/Villin-Cre mice to produce FASN/Villin-Cre, 
FASN+/∆ /Apc/Villin-Cre, and FASN∆ /∆ /Apc/Villin-Cre mouse colonies which exhibit 
a significant reduction in FASN mRNA expression (Figure 4.1 B). We show that 
both male and female mice with heterozygous deletion of FASN live significantly 
longer than their APC/Villin-Cre counterparts (Figure 4.1 C). Additionally, FASN+/∆ 
/Apc/Villin-Cre mice, both males and females, exhibit significant lower adenoma 
burden compared to APC/Villin-Cre mice alone (Figure 4.1 D-E). 
 
 Together, these data suggest that FASN is an important mediator of tumor 
initiation in the APC/Villin-Cre mouse model, implying that CD36 may play an 





4.3.2 FASN Deletion Significantly Alters Cellular Gene Expression Profile; 
Decreasing Expression of Genes Enriched in Protein Synthesis, Cell Cycle, and 
Energy-generating Metabolic Pathways  
 
To delineate the mechanism behind the phenotype observed in the 
FASN/Apc/ Villin-Cre mouse model, we performed RNA-seq analysis from tissues 
taken from the mouse lines described above. RNA-seq analysis revealed 
significant changes in mRNA expression of numerous genes between the 
APC/Villin-Cre, FASN+/∆ /Apc/Villin-Cre, and FASN∆/∆ /Apc/Villin-Cre mouse 
tissues (Figure 4.2 A-B). Because of this, we also performed gene enrichment 
analysis of these mouse tissues which demonstrated significant changes in the 
expression of genes involves in cell proliferation, energy metabolism and CRC 
initiation and progression (Figure 4.2 C), thus, supporting our data in Figure 4.1.  
 
4.3.3 FASN Knockout Alters Cellular Metabolism  
 
Further analysis of tissues collected from the mouse lines described above 
showed several alterations in genes involved in various cellular metabolic 
processes. Reverse phase protein array (RPPA) analysis revealed significant 
changes in genes involved in the TCA cycle, glycolysis, and hexosamine 
biosynthesis (Figure 4.3 A-B). Analysis of cellular metabolites was performed 
using gas chromatography-mass spectrometry (GCMS). (Figure 4.3 C). We are 
currently analyzing this data and have already identified significant changes in 
metabolites within glycolysis and its branching pathways and TCA cycle.  
  
Together, these data suggest that FASN is an important regulator of not 
only FA metabolism directly, but also various other metabolic processes in CRC, 
which could have significant impact on CRC cell growth.  
    
4.3.4 Overexpression of FASN Increases Expression of GFPT1 and OGT in vivo 
 
 Altered glycosylation is frequently associated with the onset and 
progression of CRC [323-325]. Interestingly, RPPA analysis showed that 
hexosamine biosynthesis was altered in FASN knockout mouse tissues, 
specifically two critical genes necessary for hexosamine biosynthesis, GFPT1 and 
OGT (Figure 4.4 A). To further elaborate on this, we analyzed protein expression 
of genes related to hexosamine biosynthesis as well as the product of this 
pathway, O-GlcNAc, and found that several genes and O-GlcNAc were 
downregulated in FASN knockout mouse tissues (Figure 4.4 B-C).  
 
 Our lab has also established an inducible CRE mouse model, where the 
Cre recombinase enzyme is expressed with an ERT2 promoter, allowing for 
expression of Cre only in the presence of tamoxifen. When bred with our FASN 
mouse strains, the results are the, FASN+/∆ /Apc/Villin-Cre -ERT2 and FASN∆ /∆ 
/Apc/Villin-Cre-ERT2 strains, which upon administration of tamoxifen, both FASN 




mRNA and protein expression levels of GFPT1 and OGT and found that when 
FASN is knocked out via tamoxifen, both GFPT1 and OGT expression is 
significantly reduced and comparable to that of the FASN+/∆ /Apc/Villin-Cre and 
FASN∆ /∆ /Apc/Villin-Cre strains (Figure 4.4 D-E). 
 
 These data suggest that FASN significantly regulates hexosamine 
biosynthesis via the regulation of GFPT1 and OGT gene expression, implying that 
FASN may regulate CRC initiation and progression not only through direct FA 
metabolism, but also through glycolysis.  
 
4.3.5 High Expression of GFPT1 and OGT is associated with an increase in CRC 
Proliferation and Tumorigenesis 
 
 To delineate the effect of hexosamine biosynthesis in CRC, we utilized the 
primary CRC cell line Pt93 established in our lab. The drug Azaserine is a chemical 
inhibitor of GFPT1 [327]. Treatment of Pt93 with varying concentrations of 
Azaserine results in a significant reduction in cell proliferation (Figure 4.5 A). 
Additionally, treatment of Pt93 cells with OSMI-1, a chemical inhibitor of OGT, also 
significantly reduced proliferation (Figure 4.5 A). Furthermore, treatment of both 
drugs on Pt93 also greatly reduced soft agar colony formation (Figure 4.5 B). 
Moreover, knockdown of GFPT1 and OGT in the established CRC cell line 
HCT116 reduced subcutaneous xenograft tumor volume and tumor weight in vivo 
(Figure 4.5 C-D). 
 
Cumulatively, this data suggests that hexosamine biosynthesis is a critical 
component to CRC proliferation and progression and that the enzymes GFPT1 




 The APC/Villin-Cre mouse model allows investigators to study APC driven 
adenoma formation in vivo [312]. Previous studies from our lab have demonstrated 
the role of FASN in CRC cell proliferation and tumor growth. [153, 185]. However, 
FASN has never been investigated regarding APC driven adenoma formation in 
animal models. Here for the first time, we demonstrate that FASN is significantly 
upregulated in APC/Villin-CRE mice. Additionally, we established FASN+/∆ 
/Apc/Villin-Cre and FASN∆/∆ /Apc/Villin-Cre mouse strains and found that when 
FASN expression is reduced, these mice exhibit significantly reduced tumor 
burden and survive longer than their APC/Villin-CRE counterparts. Additionally, 
through RNA-seq, gene enrichment, and RPPA analysis, we show that FASN 
knockout reduces the expression of several metabolic genes involved in the TCA 
cycle, glycolysis, and hexosamine biosynthesis.  
 
 Dysregulation of hexosamine biosynthesis, otherwise known as 
glycosylation, is frequently associated with the onset and progression of CRC [323-




limiting enzyme, and OGT, the enzyme responsible for the final step of 
glycosylation, producing O-GlcNAc [316-318]. It is suggested that levels of cellular 
O-GlcNAc may be directly regulated by FA metabolism. However, the role of 
GFPT1 and OGT in disease progression as well as any potential regulation of 
glycosylation by FASN has not yet been investigated in CRC. Our data here shows 
that when FASN expression is reduced is mouse tissues, both GFPT1 and OGT 
mRNA and protein expression is reduced. Furthermore, in the same tissues we 
also demonstrate that with a reduction in both GFPT1 and OGT, we see a 
reduction in the number of glycosylated proteins. This data suggests that FASN 
may not only regulate FA metabolism but also hexamine biosynthesis in 
APC/Villin-CRE mice. 
 
 To further elaborate on the role of GFPT1 and OGT in CRC tumorigenesis, 
we demonstrate here for the first time that inhibition of GFPT1 and OGT reduce 
cell proliferation and colony formation in vitro. Additionally, we show that 
knockdown of both GFPT1 and OGT reduced tumor volume and tumor weight in 
subcutaneous xenografts. These data further support the hypothesis that 
hexamine biosynthesis is an important metabolic pathway in the development and 




In summary, the APC/Villin-CRE mouse model in an excellent tool for the 
investigation of APC driven tumorigenesis [312]. Further investigation into the 
mechanistic drivers of this phenomenon could potentially provide new therapeutic 
avenues for the treatment of CRC. Our data here emphasizes the important role 
FASN plays in this process through the regulation of hexosamine biosynthesis. 
Furthermore, hexosamine biosynthesis itself appears to be a significant contributor 
to CRC progression and further understanding of this pathway is necessary for 
more efficacious treatment of CRC. Lastly, our data suggests that further 
understanding of the role FASN plays in APC driven tumorigenesis and targeting 



















Figure 4.1 Heterozygous Deletion of FASN Increases Survival and 
Decreases Adenoma Burden in vivo. 
(A) FASN expression in Apc/Cre mice. (B) Cre-mediated knockout of FASN in 
mouse intestinal tumors. (C) The effect of Villin-Cre-mediated heterozygous 
deletion of FASN in mouse intestinal and colon tissues on mice survival. (D) The 
effect of Villin-Cre-mediated heterozygous deletion of FASN in mouse intestinal 
and colon tissues on formation of mouse adenomas. Analysis10 cm sections of 
















Figure 4.2 FASN Deletion Significantly Changes Cellular Gene Expression. 
(A) Venn diagram displaying the overlapping genes identified in tumors from 
Apc/Villin-Cre mice and Apc/Villin-Cre mice with heterozygous and homozygous 
deletion of FASN. (B) Scatter plots showing several DEGs in Apc/Villin-Cre mice 
and Apc/Villin-Cre mice with heterozygous and homozygous deletion of FASN. 
Significantly DEGs are indicated in colors. Red and blue dots are up- and 
downregulated genes, respectively. (C) Representative gene set enrichment 
analysis (GSEA) plots generated from RNA-seq expression data of Apc/Cre and 
FASN knockout mice. The bar codes indicate the location of the members of the 
gene set in the ranked list of all genes. ES, enrichment Score; NES, normalized 











Figure 4.3 FASN Knockout Alters Cellular Metabolism. 
(A) Heat map demonstrating expression of metabolic enzyme as determined by 
the Reverse Phase Protein Array (RPPA) analysis (performed by Redox 
Metabolism Shared Resource Facility and analyzed by Biostatistics & 
Bioinformatics Shared Resource Facility). (B) The level of FASN expression by 
Western Blot of mouse tumors used for the RPPA analysis. (C) Heat map of 
metabolites determined by Gas Chromatography-Mass Spectrometry (GCMS) in 




















Figure 4.4 FASN Regulates the Expression of GFPT1 and OGT in vivo. 
(A) RNA-seq analysis volcano plots showing significant differences in the mRNA 
expression of GFPT1 and OGT in FASN knockout mouse tissues. (B) Western blot 
analysis of various enzymes involved in hexosamine biosynthesis from Apc/Villin-
Cre, FASN+/∆ /Apc/Villin-Cre, and FASN∆/∆/Apc/Villin-Cre tissues of mice. (C) 
Western blot analysis of O-GlcNAc in mouse tissues described above. (D) mRNA 
and (E) protein expression of FASN, GFPT1, and OGT in the inducible Apc/ Villin-






















Figure 4.5 GFPT1 and OGT Regulate CRC Proliferation and Tumorigenesis 
(A) Cell proliferation assays of Pt93 cell treated with azaserine, and OSMI. (B) 
Colony formation assays of Pt93 cells treated with azaserine and OSMI-1. (C) 















CHAPTER 5. CONCLUSIONS  
 
Altered fatty-acid metabolism is a hallmark of cancer and has been 
implicated in CRC progression and metastasis [128-130]. Inhibition of de novo FA 
synthesis through targeting FASN via TVB has shown some promise in pre-clinical 
studies [191-193]. However, despite of presence of high FASN expression in 
tumors, only 30% of PDXs show a positive response to TVB treatment [185]. Thus, 
there may be alternative compensatory pathways that contributes to TVB 
resistance. Such pathways may include the uptake of exogenous FAs via FA 
transporters. CD36 is a prominent exogenous FA transporter and has been shown 
to promote tumor progression in multiple diseases [149-152, 217-221]. Therefore, 
the purpose of my studies was to investigate any potential role of CD36 in CRC 
primary tumor progression and metastasis as well as any role CD36 may have in 
the resistance of FASN inhibition to possibly define new therapeutic targets for 
CRC treatment. 
 
5.1 CD36 in Primary CRC 
 
 CD36 is upregulated in primary CRC cells, patient tissues, and patient 
derived xenografts. CD36 is associated with an increase in the proliferation of 
established and primary CRC cell lines. High expression of CD36 also promotes 
tumor growth in vivo in an isogenic patient derived xenograft model. Consistently, 
pharmacological inhibition of CD36 with SSO decreases cell proliferation in vitro 
and tumor progression in vivo. This data is in parallel with most of the current 
literature, which is suggestive that CD36 plays an important role in primary tumor 
survival and disease progression in multiple cancers [149-152, 217-221].  
 
Furthermore, increased expression of CD36 was associated with increases 
in the pro-survival markers survivin and p-Akt. Survivin, a member of the inhibitor 
of apoptosis (IAP) family of proteins, is involved in the inhibition of various 
caspases including caspace-3 and 7, and thus inhibiting programmed cell death 
[328]. Akt is a crucial component of the PI3K/Akt/mTOR pathway, which is an 
important regulatory pathway for cell proliferation and survival [329]. This data is 
in agreement with previously published literature, which implicated CD36 in the 
regulation of the Src/PI3K/AKT/mTOR signaling pathway in HCC [221]. The data 
from this first study suggest that CD36 plays a role in proliferation and 
tumorigenesis in primary CRC.  
 
During the investigative process of these findings, another manuscript 
studying the potential role of CD36 in CRC was published [330]. Interestingly, Y. 
Fang et.al. found that CD36 expression inversely correlates with CRC progression 
and they demonstrated that CD36 overexpression decreases CRC cell viability and 
colony formation [330]. Their data also suggest that CD36 knockdown increases 
cell viability and colony formation. Furthermore, they state that CD36 reduces 
glycolysis through inhibition of β-catenin/c-myc signaling [330]. This data is in 




to increased glycolysis in HCC, and is in direct contrast with our findings here. One 
potential explanation to these varying results in CRC could be that between the 
two studies, a variety of CRC cell lines were used, none of which were used in 
both investigations. Our studies utilize HCT116, HT29 and isogenic HT29 cell lines 
LuM0 and LuM3, as well as primary cell lines established from PDX tumors in our 
laboratory. We also utilized a variety of patient tissues and other PDX models 
[274]. In contrast, Y. Fang et al. used 4 established CRC cell lines: SW480, LoVo, 
RKO, and CACO2 [330] and did not utilize HCT116 and HT29 cells which are most 
frequently used in publications for CRC. Even among the few CRC cell lines used 
within our investigation, we noted differences in the expression of CD36. Variances 
in the mutational profiles, metabolic reprogramming, and gene expression of these 
cell lines may account for the conflicting results observed between the two 
manuscripts.  
  
5.2 CD36 Compensates for FASN Inhibition 
  
 Previous studies from our lab have shown that inhibition of FASN via TVB-
3664 reduces cell proliferation in vitro [153, 185]. However, when analyzing the 
efficacy of TVB in pre-clinical in vivo studies using PDX models, we noted that only 
30% of PDX tumors responded positively to TVB-3664 [153, 185]. Since mice 
consume a dietary FAs present in their normal chow, we hypothesized that 
pathways involved in the uptake of exogenous FAs are of particular interest to 
investigate the mechanisms of resistance to FASN-targeted therapy.   
 
 CD36 is a well-defined FA transporter expressed in various tissues [120]. 
Analysis of the TCGA data base reveals that on the mRNA level, CD36 and FASN 
share an inverse relationship in CRC [274]. In the presence of FASN inhibition or 
knockdown, we show that CD36 is significantly upregulated in established and 
primary cell lines, tumor xenografts, genetically modified mouse models with 
knockout of FASN, and human tissues [274]. Furthermore, this upregulation of 
CD36 is extremely specific, with no significant change in the expression of other 
prominent FA transporters when FASN function is reduced in all models described 
above [274]. Additionally, knockdown of FASN upregulates the uptake of 
exogenous fluorescent FA analogues, and this increase in FA uptake is directly 
dependent on CD36 as demonstrated using a CD36 neutralizing antibody [274]. 
Together, the data presented here provides compelling evidence that inhibition of 
FASN directly upregulates CD36 to increase exogenous FA uptake and 
compensate for the lack of de novo FA synthesis. This relationship between FASN 
and CD36 had not yet been investigated in CRC. 
 
 Interestingly, our data here is further supported by one other study. It was 
shown that breast cancer cell lines which are resistant to lapatinib, a targeted 
therapeutic for HER2 positive breast cancer cells, markedly develop resistance to 
FASN inhibition [331, 332]. To note, it has been shown that FASN can be regulated 
by HER2 via phosphorylation in HER2 positive breast cancer [333]. It was 




resistance to both lapatinib and FASN inhibition. Indeed, it was shown through 
microarray analysis that CD36 is significantly upregulated in lapatinib resistant 
breast cancer cell lines and that inhibition of CD36 significantly reduces cell 
viability and proliferation [331]. Furthermore, inhibition of CD36 via a neutralizing 
antibody in mouse xenograft models sensitizes breast cancer tumors to lapatinib 
[332]. Lastly, it was also demonstrated that patients treated with anti-HER2 therapy 
display a significant upregulation in CD36 expression [332]. Together, these data 
support our findings in that, with the targeting of HER2 and thus FASN, breast 
cancer cells reprogram their metabolism to become more reliant on the uptake of 
exogenous FAs through CD36. 
 
 Due to the increasing interest in targeting FA metabolism in the treatment 
of cancer, understanding the relationships between exogenous FA uptake and de 
novo FA synthesis is critical. From the data presented here, we suggest that further 
understanding of the relationship between FASN and CD36 is necessary to 
increase the efficacy of FASN-targeted therapies as well as those drugs already 
approved for the treatment of other cancers, such as lapatinib. Furthermore, 
delineating the mechanisms behind this relationship may help to develop entirely 
new therapeutic approaches for the treatment of CRC, other cancers, or other 
metabolism dysregulated diseases.  
   
5.3 CD36 and CRC Metastasis 
 
 TMA analysis of normal colon as well as primary and metastatic CRC 
tissues showed an increase in CD36 expression in primary CRC and further 
upregulation in metastasis [274]. Furthermore, CD36 expression in metastatic 
tissues could be characterized with a stark increase in membrane associated 
CD36 [274]. Because of this association of CD36 expression with metastatic 
tissues, we developed a hypothesis that CD36 expression contributed to CRC 
progression and metastasis. 
  
 Indeed, CD36 overexpression in CRC cell lines increased cell invasion and 
colony formation in vitro and CD36 expression was associated with cells that 
exhibit a higher metastatic potential [274]. Furthermore, CD36 knockdown reduced 
lung colony formation and CD36 overexpression increased local CRC cell invasion 
and metastasis in cecum injected mice [274]. It is logical to think that increased 
CD36 expression in CRC confers metastatic potential through increased FA 
uptake and, thus, more energy resources and building blocks for cell membranes 
in these more metabolically demanding and highly proliferative cells. However, it 
is possible that CD36 may also regulate other processes involved in metastasis, 
such as EMT.  
 
 We found that CD36 expression is associated with the newest member of 
the matrix metallopeptidase family of proteins, MMP28 [290, 292]. We also show 
that knockdown of MMP28 reduces CRC cell invasion comparable to that of CD36 




its novelty; however, like other MMPs, it is implicated in the regulation of various 
extracellular matrix components [290]. Most interestingly, we found that MMP28 
expression is inversely associated with e-cadherin expression, an important 
marker for EMT in CRC [284]. As previously mentioned, e-cadherin loss is a poor 
prognostic factor for CRC patients, and it is associated with tumor invasion and 
lymph node metastasis [287]. It was previously shown that MMP28 is associated 
with EMT and e-cadherin loss in lung carcinoma [295, 296]. However, any potential 
association of MMP28 with e-cadherin has not yet been investigated. Moreover, 
the exact mechanism by which MMP28 may regulate the expression of e-cadherin 
has not yet been fully elucidated. We demonstrate here, for the first time, that 
MMP28 expression is not only associated with loss of functional e-cadherin, but 
that it is also associated with an increase in  the products of e-cadherin cleavage, 
CFT1 and CFT2 [297]. This striking insight suggests that MMP28 may very well 
directly cleave functional e-cadherin. The implications of these findings are 
significant, as the CD36-MMP28-e-cadherin association may be a novel 
mechanistic pathway of EMT regulation in CRC.  
 
With metastatic CRC survival rates remaining at terribly low levels, insight 
into mechanisms by which CRC tumors initiate metastasis are crucial for future 
treatment of CRC patients. Further investigation into the regulation of MMP28 by 
CD36 may provide the necessary information to successfully develop therapeutics 
against this phenomenon.   
 
5.4 CD36 Functions as a FA Transporter in Cancer 
 
Mechanistically, we show an increase in exogenous FA uptake as well as 
increases in both survivin and p-Akt and as described above, which mostly agrees 
with previous literature with some slight controversy [330]. The results here lead 
to the development of the hypothesis that CD36 enhances primary CRC 
proliferation and survival directly through the uptake of exogenous FAs, and thus 
increased FA metabolism. However, further investigation into exact metabolic 
pathways which are utilized in cells and tumors with high expression of CD36 is 
needed to definitively test this hypothesis. 
 
Compelling evidence exists from multiple previous publications that CD36 
plays an important role in tumorigenesis and cancer progression via FA transport 
[219, 220, 276]. As previously mentioned, it was shown that FA treatment of breast 
cancer cell lines enhances cell proliferation. Furthermore, knockdown of CD36 
abolishes cell proliferation after FA treatment, suggesting that the more 
proliferative phenotype observed with FA treatment is CD36 dependent. [219]. In 
addition to breast cancer, CD36 was shown to contribute to cervical cancer tumor 
growth and progression in a FA dependent manner. More specifically, cervical 
cancer xenograft mice fed a diet high in oleic acid exhibit increased tumor volume 
and weight [276]. However, when CD36 is inhibited, the tumorigenic phenotype 




in cervical cancer xenograft mice, which were fed normal diet, results in similar 
tumor growth as just high oleic acid diet alone [276].  
 
 Interestingly, the pro-tumorigenic effect of CD36 as a FA transporter are not 
strictly due to just the transport of various FAs. In fact, it was shown that the binding 
and transport of FAs by CD36 also induces several downstream signaling 
cascades which also contribute to disease progression [210, 221, 276]. For 
instance, in cervical cancer cells, CD36 FA transport  activates ERK 1/2 signaling 
through activating Src-kinase, as described previously [210, 276]. Furthermore, 
CD36 was found to enhance glycolysis in HCC through downstream activation of  
the Src/PI3K/AKT/mTOR signaling pathway [221]. Our data suggest that a similar 
signaling function is also present  in CRC, as we show an increase in both survivin 
and p-Akt when CD36 is overexpressed in CRC cells. 
 
 Our results support the literature in that CD36 promotes CRC through the 
uptake of exogenous FAs and the upregulation of multiple pro-survival pathways. 
Further investigation into the exact metabolic rewiring that occurs due to CD36- 
mediated FA uptake is needed and would likely shed new light on FA metabolism 
as a therapeutic target in CRC. Together, our data and the literature suggest that 
targeting CD36 from the perspective of a FA transporter may yield significant 
insight into this phenomenon and possibly provide new therapeutic strategies for 
CRC and other oncogenic diseases. 
 
5.5 Potentiality of CD36 Targeted Therapies 
 
As mentioned previously, there were multiple clinical trials which had 
targeted CD36 in relation to its role in binding TSP1 and its role in angiogenesis 
[226]. More specifically, these therapeutics were designed as TSP1 mimetics, 
mimicking the structure of TSP1 to further increase TSP1-CD36 mediated 
signaling and, thus, inhibiting angiogenesis [208, 209, 226]. Although each drug 
had shown promise in pre-clinical studies, unfortunately, each of those previous 
clinical trials  resulted in early termination due to adverse side effects, as well as 
little to no efficacy [227]. To date, there have been no pre-clinical or clinical trials 
developed aimed at targeting CD36 in cancer from the perspective of FA transport. 
 
 As the studies presented here suggest, targeting CD36 can both reduce 
CRC cell proliferation and inhibit xenograft tumor growth in vivo. Additionally, CD36 
contributes significantly to invasion and colony formation in vitro, and lung colony 
formation and orthotopic xenograft metastasis in vivo, suggesting that it is a 
potential target for metastasis. Furthermore, we show that inhibiting CD36 function 
directly decreases exogenous FA uptake, supporting the hypothesis that CD36 
promotes primary and metastatic CRC through the advantageous uptake of 
exogenous FAs which can then be used as a source of energy as well as building 
blocks for cell membranes [274]. These attributes strongly support the idea of 
developing and further investigating the effectiveness of chemotherapeutic targets 





 Previous investigations into the role of CD36 in oral carcinoma revealed that 
CD36 is a major contributor to oral carcinoma metastasis [150]. Interestingly, in 
contrast to our findings in CRC, this study shows little to no effect on primary oral 
carcinoma tumor growth when CD36 was inhibited or knocked down [150]. 
Because of these earlier findings, members from this lab have since founded a 
company, Ona Therapeutics, which is focused on the investigation of metastasis 
in numerous oncogenic diseases with the primary aim of developing 
chemotherapeutics against dysregulated lipid metabolism (Figure 5.1) [334]. As 
their flagship project, CD36 is currently their primary focus with the hopes of 
developing agents to inhibit metastasis initiation in various cancers. Our work 
presented here shows substantial evidence supporting their current work and 
suggests that CD36 is a potential therapeutic target in CRC, not only for metastasis 
but also for primary CRC development and progression. 
 
 To reiterate the potential significance of CD36 as a therapeutic target, I will 
stress again the important role CD36 plays in the compensation of de novo FA 
synthesis inhibition. Currently, the results described here regarding this 
relationship could potentially have significant clinical impact. The FASN inhibitor 
TVB and its various analogues are being tested in several pre-clinical and clinical 
trials [191-193]. Current data not only suggests that not all patients will respond 
well to FASN-targeted therapy, but also that high expression of FASN alone is not 
enough to determine whether a patient will respond positively to TVB. Identifying 
CD36 as a potential compensatory mechanism to FASN inhibition may allow for 
more efficacious treatment in combination with TVB.  
 
Chemotherapeutic targets against CD36 should be developed based on our 
results and the overwhelming evidence of CD36 as pro-tumorigenic in the 
literature. Together, the results shown here support the need for further 
investigation of CD36 to treat CRC more effectively. This further understanding will 
allow investigators, such as those working at Ona Therapeutics, to better develop 
potential drugs to target CD36. 
  
5.6 FASN Promotes APC-Driven Tumorigenesis 
 
 FASN expression is upregulated in animal tissues with Cre-mediated 
deletion of the APC gene. Heterozygous deletion of FASN in Apc/Villin-Cre mice 
leads to a significant increase in animal survival and a decrease in intestinal tumor 
burden. This data suggests that FASN may play an important role in tumor initiation 
in APC-driven tumorigenesis. 
 
 Investigations in the molecular drivers for both familial and sporadic CRC 
have resulted in several suspect genes. One such is APC, and mutations in APC 
and its role in regulating Wnt/β-catenin signaling, have been shown to be 
necessary for the initiation of FAP, and aberrant Wnt/β-catenin signaling is present 




model is an excellent tool for investigating this phenomenon [312]. Our data here 
suggests that not only is APC driving tumorigenesis through increased Wnt/β-
catenin signaling, but lack of wild-type APC also significantly upregulates FASN 
and FASN itself is a major contributor to the pro-tumorigenic phenotype seen in 
the APC/Villin-Cre mouse model. 
 
 To further investigate potential mechanisms behind FASN dependent 
tumorigenesis, we analyzed these mouse tissues for global mRNA using RNAseq 
analysis as well as performed metabolic analyses. Interestingly, we found that 
FASN significantly regulates a spectrum of cellular processes. These include cell 
cycle, cell proliferation, and multiple metabolic pathways. More specifically, we 
found that FASN is associated with an increase in glycolysis and hexosamine 
biosynthesis (glycosylation), with emphasis on the expression of two prominent 
enzymes associated with glycosylation, GFPT1 and OGT. Upon further 
investigation of the role these two enzymes might play in CRC, we showed that 
OGT and GFPT1 themselves contribute to CRC proliferation, colony formation, 
and tumorigenesis in vivo. This data suggests that FASN may help contribute to 
APC-mediated CRC initiation through enhanced hexosamine biosynthesis and 
altered glycosylation.  Based on this data, our lab has been further investigating 
the contribution of FASN to O-linked and N-linked glycosylation.   
 
 FASN, as previously mentioned, is already identified as a potential 
therapeutic target for the treatment of CRC and several clinical trials are currently 
underway using the FASN inhibitor TVB [191-193]. The data here suggests that 
treatments targeting FASN may prove more effective if the CRC tissues contain a 
mutation in APC. Additionally, targeting FASN in combination with hexosamine 
biosynthesis may yield even greater treatment efficacy. Thus, we suggest that with 
further investigation into FASN mediated tumorigenesis in CRC, from the 
perspective of alterations in metabolic processes other than direct FA metabolism, 
more effective treatment strategies for CRC may be developed.    
   
5.7 Future Directions 
 
 Through a large variety of in vitro and in vivo methods as well as in  human 
tissues, we demonstrate a significant and specific upregulation of CD36 in the 
presence of FASN inhibition or knockdown. However, the mechanistic drivers of 
this upregulation have yet to be delineated. There are multiple upstream pathways 
and effectors that can act on either FASN, CD36, or both. Both genes contain 
sequences within their promoter regions which can be targeted by the sterol-
regulatory element binding proteins (SREBPs) as well as PPARs and STAT 
proteins [200, 202, 336]. It is possible that in the absence of functionally de novo 
lipid synthesis, one or some of these regulatory pathways and transcription factors 
are upregulated in an attempt to compensate, leading to an increase in CD36 
expression and an increase in exogenous FA uptake. In addition to transcriptional 
regulation of CD36, it is worth noting that we observed an increase in membrane 




may be some post-transcriptional regulation of CD36 involved when de novo lipid 
synthesis is reduced. As previously mentioned, palmitoylation of CD36 and the 
presence of di-sulfide bridges within the protein are critical for subcellular 
trafficking of CD36 the cell membrane and its association with lipid rafts [194]. 
Further investigation to the post-transcriptional regulation of CD36 when functional 
FASN is reduced is necessary to fully delineate the association between these two 
proteins that we describe in Chapter 2. 
 
 In addition to understanding the mechanistic link between CD36 and FASN, 
further analysis of the translational effect of combining the inhibition of these two 
proteins is necessary. We show  that when we inhibit both FASN and CD36, we 
see a combinational effect on decreased cell proliferation in multiple established 
and primary cell lines. This in vitro data will need to be further elaborated on, by 
transitioning to in vivo models with combinational treatment of both TVB and a 
CD36 inhibitor. We reported in Chapter 2 that in vivo administration of SSO, an 
inhibitor of CD36,  significantly decreases  subcutaneous xenograft tumor growth 
but has no significant effect on animal body weight. This is encouraging and 
suggests that a combination administration of  both TVB and SSO may be 
possible. There are companies actively developing inhibitors against CD36 with 
clinical intent, such as Ona Therapeutics [334]. It is a possibility that if SSO proves 
to be too toxic when used in combination with TVB in vivo, that novel inhibitors 
may prove useful in such an investigation. 
 
Although we demonstrate the important role CD36 plays in the proliferation, 
tumorigenesis, and metastasis of CRC, more work is needed to delineate exact 
mechanisms responsible for this phenomenon. One potential mechanism is the 
direct uptake of exogenous FAs in the presence of increased CD36 expression, 
leading to increased FA metabolism. We show in Chapter 2 that with increases in 
CD36 expression, we observe an increase in the uptake of exogenous FA 
analogues. However, the specific types of FAs up taken by CD36, and their fate 
are not known. 
 
There are several methods utilized today to study various metabolic 
pathways which are enhanced in cancers cells. The cutting edge of these methods 
is known as carbon-13 (13C) metabolic flux analysis [337]. This method involves 
the labeling of a particular metabolic substrate, such as glucose or FAs, with a 
stable isotope of carbon, such as 13C. When these molecules are  metabolized by 
the cell, the downstream metabolites are consequently labeled in a unique pattern 
by the isotopes, which can be measured using techniques such as mass 
spectrometry (MS) or nuclear magnetic resonance (NMR) [337]. Metabolic tracing 
studies utilizing 13C labeled long-chain FAs of varying length could yield new 
insights into the types of FAs CD36 uptakes in CRC and ultimately how those FAs 
are utilized. Furthermore, Seahorse analysis of extracellular acidification rate 
(ECAR) and oxygen consumption rate (OCR) on CRC cell lines utilized in Chapter 
2-3, such as the CD36 knockdown and overexpression cell lines, is necessary to 




glycolysis. These investigations will be critical in determining the role CD36 plays 
in CRC tumorigenesis via direct increased exogenous FA uptake. 
 
In addition to increased FA uptake and potentially an increased in FA 
metabolism, we also observed as association between CD36 expression and that 
of p-AKT and survivin. However, mechanistic links between CD36 expression and 
increases in both survivin and p-AKT have not yet been delineated. Recently, it 
has been shown that palmitic acid (PA) alone induces migration and invasion of 
gastric cancer cells in a CD36 dependent manner [338]. Thus, PA treatment 
studies in combination with altered expression or inhibition of CD36 in CRC could 
determine if the increased activation of the AKT pathway and an increase in 
survivin expression are directly related to exogenous PA up taken by CD36.  
 
Aside from the pro-tumorigenic and proliferative properties of CD36 in CRC 
that we describe here, we also demonstrate that CD36 significantly promotes CRC 
metastasis. We showed that CD36 expression is associated with the newest 
member of the matrix metallopeptidase family of proteins, MMP28, and that 
MMP28 is associated with cleavage of e-cadherin. However, any direct 
mechanistic link between CD36 expression and that of MMP28 remains elusive. 
Being the most novel member of this family of proteins, resources on the MMP28 
gene are limited, however, the gene has been sequenced. Other members of the 
MMP family have promoter sequences for tumor necrosis factor alpha (TNFα) as 
well as binding sites for NF-kB, signal transducers and activators of transcription 
(STAT) proteins downstream of EGF signaling, and TGFβ [339-341]. Previous 
studies in hepatocellular carcinoma have demonstrated that FFA treatment 
promotes EMT in a CD36 dependent manner through increased activation of TGFβ 
signaling [222]. In depth analysis of the promoter region of the MMP28 gene 
sequence is necessary to identify potential enrichment sites for promoters, such 
as TGFβ, that could potentially link MMP28 and CD36 mechanistically. Such future 
investigations will shed new light on CD36 and its role not only in CRC and CRC 
metastasis, but potentially yield new insight into roles CD36 may play in other 
diseases. 
 
Lastly, we show here that FASN promotes APC-driven tumorigenesis in 
CRC and does so through the regulation of hexosamine biosynthesis. Further 
investigation into the potential of targeting both de novo lipid synthesis and 
hexosamine biosynthesis in combination will need to be performed both in vitro 
and in vivo. Additionally, because of the significant reduction in tumor burden 
observed in mice with FASN heterozygous knockout, it is possible to target FASN 
via TVB in the APC/Villin-Cre mouse model to further investigate this phenomenon. 
Analysis of current patient data basis for the expression patterns of both FASN 
and mutant APC will need to be performed and could identify potential correlations 
between these two genes and CRC patient prognosis. Together, the data 
presented here and that of future investigations described could further delineate 





5.8 Final Thoughts 
 
 CRC patients with distant metastatic disease are still in desperate need for 
new therapeutic interventions. Stage IV CRC patients have severely low 5-year 
survival rates and disease relapse is prominent amongst most patients. 
Investigation into altered molecular and metabolic pathways that drive CRC 
progression and metastasis is necessary to develop more effective treatments. 
Altered FA metabolism is emerging as a prominent target for the treatment of CRC, 
and studies from our lab have already demonstrated some of the importance that 
de novo FA synthesis via FASN plays in CRC progression and metastasis. The 
results of the studies described here also identify CD36, a prominent FA 
transporter expressed in CRC, as a new potential therapeutic target for this 
devastating disease. We further emphasize the striking relationship between 
FASN and CD36, especially the upregulation of CD36 when FASN is effectively 
inhibited. This is particularly important as TVB inhibitors against FASN are 
currently in clinical trials. Aside from this compensation, we also describe the pro-
tumorigenic and metastatic properties of CD36 in the regulation of pro-survival 
markers and e-cadherin cleavage via MMP28 and suggest that targeting CD36 
could yield positive clinical results in CRC. Furthermore, we identified other pro-
tumorigenic properties of FASN, as shown using the APC/Villin-Cre mouse model 
and how FASN can regulate cellular metabolism, particularly, hexosamine 
biosynthesis.  
 
Together, the data from the studies presented here offer new insights into 
the complex regulation of FA metabolism in CRC. Further investigation into 
mechanistic drivers behind CD36-mediated CRC progression and metastasis are 
necessary to develop new chemotherapeutics. Additionally, further understanding 
of CD36’s role in the compensation of FASN inhibition and the regulation of 
glycosylation by FASN, could drastically improve the treatment efficacy of the 
clinical trial drug TVB. Cumulatively, these studies show significant promise of 
targeting lipid metabolism in the future development of treatment strategies for 












Figure 5.1 Targeting Metastasis via FA uptake. 
Schematic showing antibody targeting of CD36 as a potential therapeutic model 
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APPENDIX 1. METHODS FOR CHAPTER 2 
 
Colon Cancer Established and Primary Cell Lines 
 
 Established cell lines HCT116, HT29, and HT29LuM3 were maintained in 
McCoy’s 5A medium supplemented with 10% FBS (Sigma-Aldrich, St. Louis, MO) 
and 1% penicillin–streptomycin. Primary colon cancer patient Pt 93 and Pt 130 
cultures were isolated and established from PDX tumors as previously described 
(1). Cells were maintained as monolayer culture in DMEM supplemented with 10% 
FBS (Sigma-Aldrich, St. Louis, MO) and 1% penicillin–streptomycin. Primary Pt 93 
and Pt 130 colon cancer cells were authenticated as unique human cell lines 
(Genetica). Established CRC cell lines were authenticated using STR DNA 
profiling (Genetica, Cincinnati, OH). Stable CD36 knockdown HCT116, HT29, and 
HT29LuM3 cell lines were established using CD36 shRNAs from Sigma-Aldrich 
(TRCN000005699, TRCN0000057000, and TRCN0000057001). Cells were 
selected with 10mg/mL puromycin. Knockdown was confirmed via quantitative 
real-time PCR (qRT-PCR) after cell selection and prior to performing animal 
experiments. Overexpression cell lines were established by transfecting HCT116 
cells with either pCMV-Spark-CD36 (Sino Biological Inc. NM 001001547.2), td-
Tomato-CD36 (Addgene, Plasmid #58077). 
 
Tissue Microarray Analysis-Immunohistochemistry 
 
 Immunoreactivity scores of CD36 and FASN expression were analyzed in 
matched normal colon mucosa and tumor tissues from patients diagnosed with 
Stage I-IV CRC who had surgery at UK Chandler Medical Center (TMA ID 
BH15991A, n = 56) by a GI pathologist (EYL) blinded as to tumor stage. The final 
immunoreactivity score was determined by multiplication of the values for staining 
intensity (0, no staining; 1, weak; 2, moderate; 3, strong staining) and the values 
for percentage of positive tumor cells (0, no positive cells; 1, 0–10%; 2, 11–50%; 







 Tissues were obtained from consented patients with Stage II-IV CRC who 
had undergone surgery at UK Medical Center (IRB #16-0439-P2H). 6–8-week-old 
NSG mice (NOD.Cg-Prkdc Il2rg /SzJ) from The Jackson Laboratory (Bar Harbor, 
ME) were used for PDX models. All procedures were performed using protocols 
approved by the UK Animal Care and Use Committee. Briefly, CRC tissues (2–5 
mm) obtained from CRC patients of both sexes were implanted subcutaneously 
into their flanks in a small pocket surgically created under the skin. Established 
tumors were designated as generation 0 (G0). Tumor tissues from G0 were minced 
and mixed with Matrigel to ensure homogeneous distribution of tissues among 
mice and allow implantation of an equal volume of tumor tissues into the flank. 
Tumor tissues were resected when they reached an appropriate size and digested 
as previously described [1]. For evaluation of CD36 expression in PDX models, we 
utilized tissue samples from Pt 2402 PDX model established from a patient 
diagnosed with metastatic adenocarcinoma (lung) consistent with colon primary 
tumor [1]. Pt 2402 PDX tumors were grown to approximately 200 mm3 then tissues 




 Individual cells from PDX model Pt 2402 were stained for CD36 with 
fluorescent antibody (Abcam ab23680). Stained cells were sorted via flow 
cytometry and the top 10% of GFP positive CD36 expressing cells (CD36high) and 
the bottom 10% of GFP negative cells (CD36low) were sorted separately from the 
rest of the tumor cell population. CD36high and CD36low were mixed with 100 μL of 
30% Matrigel and subcutaneously injected into NSG mice. Tumor growth was 
monitored for three months. Samples were taken from subsequent tumors for 
western blot analysis and immunohistochemistry and the remaining tumor tissue 




 HCT116, NTC and FASN shRNA, cells were plated at 10,000 cells/well on 
an 8-well coverslip u-slide (Ibidi #80826) and treated with CD36 neutralizing 
antibody (Cayman Chemical #1009893) for 24 hrs. After incubation with 
neutralizing antibody, cells were then treated with fluorescent FA analogue 
BODIPY FL (Thermo Fisher #D3822) for 10 minutes in serum free McCoy’s 5A 
medium supplemented with 10% FA free BSA. Cells were washed twice with PBS 
and fixed with PBS containing 5% formalin for 20 minutes at 37C. Cell were then 
imaged via confocal microscopy using a Nikon A1 Confocal Microscope. 
 





 CRC cell lines were plated onto 24 well plates at a concentration of 30,000 
cells per well. Cells were given DMEM medium for Pt 93 and Pt 130 and McCoy’s 
5A medium for HCT116 with and without fetal bovine serum to simulate starvation 
conditions. Cells were also treated with or without 100 μM SSO (Cayman 
Chemical) or 0.2 μM TVB-3664 or both. TVB-3664 was provided by Sagimet 
Biosciences (Menlo Park, CA).Cells were incubated at 37°C for 6 days. After the 
incubation period, cells were trypsinized and collected individually based on well 
and condition of treatment. Cells were counted using a Vi-Cell XR Cell Viability 
Analyzer (Beckman Coulter #C19196). HCT116, NTC and CD36 shRNA (#2 and 
#4), cells were plated onto 24 well plates at a concentration of 30,000 cells per 
well. Cells were cultured in McCoy’s 5A medium with and without fetal bovine 
serum for 72hr and counted as described above.  
 
Quantitative Real-Time PCR 
 
 Total RNA was isolated using an RNeasy mini kit (QIAGEN). cDNA was 
synthesized using a high-capacity cDNA reverse transcription kit (Applied 
Biosystems). QRT-PCR was carried out using a TaqMan Gene Expression Master 
Mix (#4369016) according to manufacture protocol and TaqMan probes for human 
CD36 (ID Hs00354519 m1), human FASN (ID Hs01005622 m1), human FATP3 
(ID Hs00354519 m1), human FATP4 (Hs00192700 m1) and human GAPDH 





NU/NU mice were injected subcutaneously with 1.0 x 106 cells of HCT116 
NTC (non-targeted control, n=7), shCD36 #2 (n=6) or shCD36 #4 (n=7) in 100 μL 
PBS and tumor growth was monitored. Tumor size was measured via calipers 
every three days and tumor volume was calculated using the formula: TV = width2 
x length / 0.52. When NTC tumor growth reached approximately 200 mm3, all mice 
were sacrificed, and tumor weight was taken via digital scale. NU/NU mice were 
injected subcutaneously with 2.0 x 106 cells of NTC (n=5) and shCD36 #4 (n=5) in 
100 μL PBS for HT29 and HT29 LuM3 xenografts experiments.  
 
Genetically Modified Mice 
 
 C57BL/6J mice with LoxP-flanked FASN alleles were obtained from Clay 
Semenkovich, MD at Washington University, and FASN/VillinCre and 
FASN/Apc/VillinCre mouse colonies were established by mating these mice with 







APPENDIX 2. METHODS FOR CHAPTER 3 
 
Colon Cancer Established and Isogenis Cell Lines 
 
Established cell lines HCT116, HT29, and HT29LuM3 were maintained in McCoy’s 
5A medium supplemented with 10% FBS (Sigma-Aldrich, St. Louis, MO) and 1% 
penicillin–streptomycin. HT29 LuM0 and LuM3 cell lines were established as 
previously described [254]. Stable CD36 knockdown HCT116, and HT29LuM3 cell 
lines were established using CD36 shRNA from Sigma-Aldrich 
(TRCN0000057001). Cells were selected with 10mg/mL puromycin. Knockdown 
was confirmed via quantitative real-time PCR (qRT-PCR) after cell selection and 
prior to performing in vitro and in vivo experiments. Overexpression cell lines were 
established by transfecting HCT116 and HT29 LuM0 cells with either pLenti-C-
Myc-DDK-P2A-Puro-CD36 overexpression (OriGene # RC221976L1V) or pLenti-
C-Myc-DDK-P2A-Puro-Empty-Vector (OriGene #PS1000064) lentiviral 
transduction particles. MMP28 knockdown cell lines were generated by 
transfecting HCT116 cells with siMMP28 siRNA (Invitrogen #87705767) or 
scrambled siRNA control in combination with Lipofectamine RNAiMAX 
Transfection Reagent (Thermo Fisher #13778150). MMP28 knockdown was 
verified by qRT-PCR and western blot. Cells were transfected for 48hrs prior to in 
vitro experiments performed.  
 
Quantitative Real-Time PCR 
 
 Total RNA was isolated using a RNeasy mini kit (QIAGEN). cDNA was 
synthesized using a high-capacity cDNA reverse transcription kit (Applied 
Biosystems #4368814). QRT-PCR was carried out using a TaqMan Gene 
Expression Master Mix (Applied Biosystems #4369016) according to manufacture 
protocol and TaqMan probes for human CD36 (Thermo Fisher #4331182-
Hs00169627_m1), MMP28 (Thermo Fisher #4331182-Hs00425232_g1), e-
cadherin/CDH1 (Thermo Fisher #4331182-Hs01023895_m1), and GAPDH 
(Thermo Fisher #4331182-Hs02786624_g1). 
 
Trans-Well Invasion Assay 
 
 HCT116 CD36 Overexpressing and CD36 knockdown cell lines were plated 
and starved for 48hrs on 100 mm petri dishes with McCoy’s 5A medium without 
FBS supplementation. Corning 24-well BioCoat™ Matrigel® Invasion Chambers 
(Corning # 354480) were rehydrated for 2hrs with McCoy’s 5A medium not 
supplement with FBS at 37C. HCt116 cell lines were then trypsinized and counted 
using a Beckman Coulter Vi-Cell BLU Cell Viability Analyzer (Beckman Coulter 
#C19196) and plated at 50,000 cells/chamber in serum free with McCoy’s 5A 
medium. Invasion chambers were then placed in wells containing 400 uL of 
McCoy’s 5A medium supplemented with 10% FBS as a chemoattractant. Cell were 
allowed to invade for 48hrs. Chambers were then aspirated, the inside wiped with 




#C6158-50G) for 10 minutes. Chambers were imaged and then de-stained using 
extraction buffer from the CytoSelect Cell Invasion Assay Kit (Cell Biolabs Inc. # 
CBA-111-T). Extracts were plated on a 96 well plate and absorbance was 
measured at 560 nm on a microplate reader for cell invasion quantification. 
 
Colony Formation Assay 
 
 6-well cell culture plates were first layered with 2% soft agar using 
SeaPlaqueTM GTG Agarose (Lonza #50115) melted in Milli-Q water. HCT116 and 
HT29 LuM0 CD36 overexpressing cells were tripsinized and counted as described 
above. Cells were mixed with a 1.5% soft agar and 2X McCoy’s 5A medium 
solution and plated at a concentration of 5,000 cells/well. McCoy’s 5A medium 
supplemented with 10% FBS was placed on top of both agarose layers and media 
levels monitored. Colonies were allowed to grow for 14 days then stained with 
0.1% crystal violet (Millipore sigma #C6158-50G) for 2hrs at room temperature. 
Wells were then washed with Milli-Q water to remove excess crystal violet stain 




 HT29-GFP-Luc. LuM0 and LuM3 cells were plated at a concentration of 
10,00 cells/chamber onto u-Slide 8 well chambered coverslips (Ibidi #80826) in 
400ul McCoy’s 5A medium supplemented with 10% FBS for 48hrs. Cells were then 
fixed with 10% Formalin for 10 minutes followed by permeabilization with 1% Triton 
X. Cells were then blocked with 1% bovine serum albumin (BSA) for 20 minutes at 
room temperature. Cells were incubated with primary antibodies for CD36 (Santa 
Cruz # sc-7309), and MMP28 (Abcam #ab175937) in 1% BSA for 2hrs at room 
temperature. Cells were then washed 3X with PBS and incubated with fluorescent 
secondary antibodies (Invitrogen #A11032 and # A32728) in 1% BSA for 1hr at 
room temperature. Chambers were washed 3X with PBS and incubated with 
Hoechst and Phalloidin stains for 20 minutes. Chambers were then imaged using 
a Nikon A1 Confocal Microscope.  
 
FA Uptake Assay 
 
HT29-GFP-Luc. LuM0 and LuM3 cells were plated at 10,000 cells/well on 
an 8-well coverslip u-slide (Ibidi #80826) and treated with CD36 neutralizing 
antibody (Cayman Chemical #1009893) for 24 hrs. After incubation with 
neutralizing antibody, cells were then treated with fluorescent FA analogue 
BODIPY ™ 558/568 C12 (Thermo Fisher # D3835) for 10 minutes in serum free 
McCoy’s 5A medium supplemented with 10% FA free BSA. Cells were washed 
twice with PBS and fixed with PBS containing 5% formalin for 20 minutes at 37C. 








 HT29-LuM3-GFP-Luc. NTC (n=5) and shCD36 (n=5) cell lines were 
aliquoted into PBS at a concentration of 1.0x10^6 cells/100ul and injected via tail-
vein into 6–8-week-old NSG mice (NOD.Cg-Prkdc Il2rg /SzJ). After 9 weeks, lung 
colonization was first imaged via a luciferase reporter assay and a Lago Spectral 
Imaging System (Lago SII). Live mice were administered 100ul of D-luciferin at a 
concentration of 3mg D-luciferin/20kg mouse via intraperitoneal injection. After 10 
minutes, mice were imaged, and bioluminescent signal was quantified using the 
Lago SII. After live imaging, mice were sacrificed, and lungs resected and imaged 





 Cecum injections were performed as previously described [299]. HCT116 
CD36 overexpression (n=5) and Control (n=5) cells were aliquoted in PBS at a 
concentration of 1.0x10^6 cells/50ul and injected into the cecal wall of NU/NU 
mice. After 10 weeks, mice were sacrificed and imaged for tumor burden within the 
cecum, colon, and intestine. Cecum tissues were collected for IHS as described 
below.  
 
RNA-Seq and Gene Enrichment Analysis 
 
RNA samples extracted from HT29-LuM0-GFP-Luc. Control and CD36 
Overexpression cell lines were analyzed via RNA-Seq by BGI Genomics, 
Cambridge, MA. Gene enrichment analysis was performed on HT29-LuM0-GFP-
Luc. Control and CD36 Overexpression cell lines by the Biostatistics and 
Bioinformatics Shared Resource Facility at the University of Kentucky, Lexington, 
KY.  
 




 C57BL/6J mice with LoxP-flanked FASN alleles were obtained from Clay 
Semenkovich, MD at Washington University and FASN/VillinCre, FASN+/∆ 
/Apc/Villin-Cre and FASN∆/∆ /Apc/Villin-Cre mouse colonies along with their ERT2 
derivatives were established in Dr. Zaytseva’s laboratory. 
 
Animal Survival Studies 
 
 Wild type and FASN heterozygous knockout mouse strains, both male and 




and their life span in days was counted.  Tissues were collected for imaging of 
tumor burden.  Number of adenomas was counted within 10 cm of small intestine 
(starting) 1 cm from the cecum.  Swiss rolls were prepared to confirm histology and 
perform IHC on FASN, Ki67 and other markers.  qRT-PCR and western blot 




 Isolated tumors from mouse strains described above were removed from 
cryostorage and transferred to a mircovial set for use with a Freezer/Mill Cryogenic 
Grinder (SPEX SamplePrep model 6875D). Tissue was pulvierzied to 5um 
particles. Metabolites were extracted directly from the microvial by the addition of 
1 ml of 50% methanol containing 20 M L-norvaline (procedural, internal control) 
and separated into polar (aqueous layer) and insoluble pellet 
(protein/DNA/RNA/glycogen) by centrifugation at 4°C, 15,000rpm for 10 minutes. 
The pellet was subsequently washed four times with 50% methanol and once with 
100% methanol to remove polar contaminants. The pellet was then hydrolyzed in 
200ul of 3N hydrochloric acid and then neutralized with 200ul of 100% methanol. 
The polar and pellet fraction was dried at 10-3 mBar using a SpeedVac (Thermo 
Fisher) followed by derivatization. The insoluble pellet was hydrolyzed similar to 
the technique described in [342]. 
 
Sample Derivatization and Gas Chromatography-Mass Spectrometry 
Quantificantion 
 
 Dried polar and insoluble samples were derivatized by the addition of 50ul 
20 mg/ml methoxyamine hydrochloride in pyridine, vortexed thoroughly and 
incubated for 1.5 hrs at 30°C. Sequential addition of 80ul of N-methyl-trimethylsilyl-
trifluoroacetamide (MSTFA) followed with an incubation time of 30 minutes at 37°C 
with thorough vortexing between addition of solvents. The mixture was then 
transferred to an amber, v-shaped glass chromatography vial and analyzed by 
GCMS. 
 
 An Agilent 7800B gas-chromatography coupled to a 5977B mass 
spectrometry (GCMS) detector was used for this study.  GCMS protocols were 
similar to those described previously[343, 344] except a modified temperature 
gradient was used for GC: Initial temperature was 130C, held for 4 minutes, rising 
at 6C/minutes to 243C, rising at 60C/minutes to 280C, held for 2 minutes. The 
electron ionization (EI) energy was set to 70 eV. Scan (m/z:50-800) and full scan 
mode were used for metabolomics analysis. Mass spectra were translated to 
relative metabolite abundance using MassHunter MS quantitative software 
matched to the FiehnLib metabolomics library (available through Agilent) for 
retention time and fragmentation pattern[344-346]. Relative abundance was 
corrected for recovery using the L-norvaline standard and adjusted to protein input 







Reverse Phase Protein Array 
 
The RPPA was performed by the Redox Metabolism Shared Resource 
Facility at The University of Kentucky. The raw RPPA data from mouse tissues 
described above was obtained in 6 dilution steps and was processed based on the 
following procedure. Firstly, data quality control was performed by plotting the 
relationship between background corrected intensity and dilution step. Proteins 
with low measurement quality as reflected by large variation across replicates or 
unreliable curve trend were excluded. Secondly, nonlinear curve fitting for the 
background corrected intensity vs dilution step was applied based on the “serial 
dilution curve” algorithm [347] to infer the concentration of each protein in the 
original undiluted sample. Due to the low protein concentration measurement in 
the 6th dilution step, the nonlinear curve fitting was only based on data from the 
first 5 dilution steps. Thirdly, protein concentrations were log2-transformed and 
normalized based on the median normalization method as described in [348] and 
[349]. Finally, the Wilcoxon Rank Sum test was used for differential expression 
analysis comparing between experimental groups. Multiple comparisons 
adjustment was performed by the Benjamini and Hochberg method. Differentially 
expressed proteins were identified by false discovery rate < 0.05. Heatmap and 
volcano plots were generated to demonstrate the relative expression changes of 
proteins of interest.  
 
RNA-Seq and Gene Enrichment Analysis 
 
RNA samples extracted FASN/VillinCre and FASN+/∆ /Apc/Villin-Cre were 
analyzed via RNA-Seq by BGI Genomics, Cambridge, MA. Gene enrichment 
analysis was performed on these same tissues by the Biostatistics and 
Bioinformatics Shared Resource Facility at the University of Kentucky, Lexington, 
KY.  
Colon Cancer Established and Primary Cell Lines 
 
 The established cell line HCT116 was maintained in McCoy’s 5A medium 
supplemented with 10% FBS (Sigma-Aldrich, St. Louis, MO) and 1% penicillin–
streptomycin. HCT116 NTC, shGFPT1, and shOGT were stablishged via 
transfection of lentiviral particles targeting GFPT1, OGT, or non-targetd control (   
). Cells were selected with 10mg/mL puromycin. Knockdown was confirmed via 
quantitative real-time PCR (qRT-PCR) after cell selection and prior to performing 
animal experiments. Primary colon cancer patient Pt 93 and Pt 130 cultures were 
isolated and established from PDX tumors as previously described (1). Cells were 
maintained as monolayer culture in DMEM supplemented with 10% FBS (Sigma-
Aldrich, St. Louis, MO) and 1% penicillin–streptomycin. Primary Pt 93  





Cell Proliferation Assay 
 
 Pt93 cells were plated onto 24 well plates at a concentration of 30,000 cells 
per well in DMEM medium with 10% FBS and 1% penicillin–streptomycin Cells 
were treated with varying concentrations of azaserine (Millipore Sigma #A4142-
50MG) or OSMI1 (Millipore Sigma #SML1621-5MG). Cells were incubated at 37°C 
for 48 hrs. After incubation period, cells were trypsinized and collected individually 
based on well and condition of treatment. Cells were counted using a Vi-Cell XR 
Cell Viability Analyzer (Beckman Coulter #C19196).  
 
Colony Formation Assay 
 
6-well cell culture plates were first layered with 2% soft agar using 
SeaPlaqueTM GTG Agarose (Lonza #50115) melted in Milli-Q water. Pt93 cells 
were tripsinized and counted as described above. Cells were mixed with a 1.5% 
soft agar and 2X McCoy’s 5A medium solution and plated at a concentration of 
5,000 cells/well. McCoy’s 5A medium supplemented with 10% FBS and containing 
20uM of either azaserine or OSMI-1, was placed on top of both agarose layers and 
media levels monitored. Colonies were allowed to grow for 14 days then stained 
with 0.1% crystal violet (Millipore sigma #C6158-50G) for 2hrs at room 
temperature. Wells were then washed with Milli-Q water to remove excess crystal 
violet stain then imaged and colony diameter measured. 
 
Quantitative Real-Time PCR 
 
 Total RNA was isolated using a RNeasy mini kit (QIAGEN). cDNA was 
synthesized using a high-capacity cDNA reverse transcription kit (Applied 
Biosystems #4368814). QRT-PCR was carried out using a TaqMan Gene 
Expression Master Mix (Applied Biosystems #4369016) according to manufacture 
protocol and TaqMan probes for human FASN (Thermo Fisher #4331182- 
Hs01005622_m1), GFPT1 (Thermo Fisher #4331182-Hs00899865_m1), OGT 






NU/NU mice were injected subcutaneously with 1.0 x 106 cells of HCT116 
NTC (non-targeted control, n=5), shGFPT1 (n=5) or shOGT (n=7) in 100 μL PBS 
and tumor growth was monitored. Tumor size was measured via calipers every 
three days and tumor volume was calculated using the formula: TV = width2 x 
length / 0.52. When NTC tumor growth reached approximately 200 mm3, all mice 
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